There is no better option than our VCS-413 exam dumps and cram

You will get the exactly same replica of VCS-413 real exam questions that you are going to attempt in actual test. Killexams.com has maintained database of VCS-413 cram that is big questions bank highly pertinent to VCS-413 and served by test takers who attempt the VCS-413 exam and passed with high score.

Exam Code: VCS-413 Practice exam 2022 by Killexams.com team
VCS-413 Administration of Veritas eDiscovery Platform 8.2 for Administrators

Exam Title : Veritas Certified Specialist (VCS) - eDiscovery
Exam ID : VCS-413
Exam Duration : 105 mins
Questions in exam : 75-85
Passing Score : 69%
Exam Center : Pearson VUE
Real Questions : Veritas eDiscovery Platform Administration Real Questions
VCE practice exam : Veritas VCS-413 Certification VCE Practice Test

System Administration
- Explain the core features and functionality of Veritas eDiscovery Platform and communicate its benefits.
- Describe the components of the installation prerequisites, and the process for installing/upgrading and configuring Veritas eDiscovery Platform.
- Describe which components require backup, how to recover, or how to configure the Veritas eDiscovery Platform.

Legal Hold
- Given a scenario, describe the procedures for creating and managing legal hold notices, including but not limited to; immediate and scheduled delivery, reminders, escalations, Notice Library, Mail-Merge, tracking, reporting, and releasing.
- Describe custodian management, including but not limited to; the custodian portal, surveys, survey response reports, and audit reports.
- Describe legal hold notice architecture, including but not limited to; Active Directory Integration and legal hold configuration.

Identification and Collection
- Describe the Interactive Data Map functionality, including but not limited to; mapping custodians to data sources, identifying potential sources of data, creating connections to sources, searching and browsing data by group, custodian, or data type.
- Describe the integrations with Enterprise Vault and Enterprise Vault.cloud, including but not limited to; Enterprise Vault Direct Collector, Enterprise Vault Collection Filters, and preserving in Enterprise Vault.
- Identify the correct collector and filter to use, including but not limited to; Network Collector, On-site Collector, Extended SharePoint Collections, Metadata filters, Keyword filters, Collection filters, Office 365, and Collection Scheduler.
- Identify when to perform full collections, incremental collections or use collection templates and prepare data for processing with Veritas eDiscovery Platform.
- Confirm data collection and perform basic troubleshooting using Data Verification, Collection History, Microsoft Rights Management System and Environment Support and Collection Analytics.

Pre-processing, Processing, Search and Analysis
- Performing pre-processing and processing, including but not limited to; setting up and performing discovery on data, configuring pre-processing options, applying processing settings, exceptions, jobs, troubleshooting, deduplication, Load File Import, Load File Configurator, and providing various language support.
- Describe the various search features, including but not limited to; search preview, search filters, search reports, saving searches, concept search, audio search, freeform search, and Automation Rules.
- Describe the various keyword search features, including but not limited to; search syntax, transparent search, multi-keyword searches, and advanced searches.
- Performing analysis on search results, including but not limited to; discussion threads, find similar, participant analytics, term analytics, and near-duplicate identification.

Review and Production
- Applying review concepts, including but not limited to; creating and managing tag lists, creating and managing folder lists, performing bulk-tagging operations, using Near-Native viewer, performing redaction and auto-redaction, smart sampling, and review reporting.
- Performing production and export, including but not limited to; native and image-based productions, Bates stamping, integrated production folders, export and production management, slip sheets, Metadata Exports, Native-Only Exports, Production Export, and export and production scalability.
- Describe Transparent Predictive Coding, best practices, and sample workflows.

System and Case Management and Reporting
- Managing cases, including but not limited to; create new cases, case analytics, create and manage access groups, multi-case architecture, configuration, and eDiscovery Dashboard.
- Using the reporting functionality in Veritas eDiscovery Platform, including but not limited to; lifecycle reporting, audit trail reporting, and activity reporting.
- Describe system management, including but not limited to; Clearwell Utility, Clearwell Commander, system settings, Veritas eDiscovery Platform services, distributed architecture (including sub-nodes, utility nodes, cluster master, and case home) and backup and restore.
- Managing users and custodians.

Administration of Veritas eDiscovery Platform 8.2 for Administrators
Veritas Administration availability
Killexams : Veritas Administration availability - BingNews https://killexams.com/pass4sure/exam-detail/VCS-413 Search results Killexams : Veritas Administration availability - BingNews https://killexams.com/pass4sure/exam-detail/VCS-413 https://killexams.com/exam_list/Veritas Killexams : Veritas InfoScale Availability 8.0 for UNIX/Linux: Administration

The Veritas InfoScale Availability 8.0 for Unix/Linux: Administration course is designed for IT professionals tasked with installing, deploying, configuring, and maintaining Veritas Cluster Server (VCS) clusters. This course discusses how to use InfoScale Availability to manage applications and databases in high availability environments and Cloud environments. The course is designed to enable you to gain the necessary fundamental and advanced skills that are required to manage a highly available application in a cluster. It also discusses how to deploy InfoScale Availability in the lab environment to practically implement a sample cluster design and deployment.

Tue, 01 Mar 2022 21:38:00 -0600 en-US text/html https://www.veritas.com/services/education-services/training-courses/infoscale-availability-8-0-admin
Killexams : Oracle and Microsoft Announce Availability of Oracle Database Service for Microsoft Azure

Oracle partners with Microsoft to supply Azure customers direct, streamlined access to Oracle databases on Oracle Cloud Infrastructure

AUSTIN, Texas and REDMOND, Wash., July 20, 2022 /PRNewswire/ -- Oracle Corp and Microsoft Corp today announced the general availability of Oracle Database Service for Microsoft Azure. With this new offering, Microsoft Azure customers can easily provision, access, and monitor enterprise-grade Oracle Database services in Oracle Cloud Infrastructure (OCI) with a familiar experience. Users can migrate or build new applications on Azure and then connect to high-performance and high-availability managed Oracle Database services such as Autonomous Database running on OCI.

Offering Customers Choice with Azure and OCI Multicloud Capabilities

Over the last two decades, thousands of customers have relied on Microsoft and Oracle software working well together to run their business-critical applications. As customers migrate applications and data to the cloud, they continue to look for joint solutions from their trusted software partners. Since 2019, when Oracle and Microsoft partnered to deliver the Oracle Interconnect for Microsoft Azure, hundreds of organizations have used the secure and private interconnections in 11 global regions.

Microsoft and Oracle are extending this collaboration to further simplify the multicloud experience with Oracle Database Service for Microsoft Azure. Many joint customers, including some of the world's largest corporations such as AT&T, Marriott International, Veritas and SGS, want to choose the best services across cloud providers to optimize performance, scalability, and the ability to accelerate their business modernization efforts. The Oracle Database Service for Microsoft Azure builds upon the core capabilities of the Oracle Interconnect for Azure and enables customers to more easily integrate workloads on Microsoft Azure with Oracle Database services on OCI. There are no charges for using the Oracle Database Service for Microsoft Azure, the Oracle Interconnect for Microsoft Azure or data egress or ingress when moving data between OCI and Azure. Customers will pay only for the other Azure or Oracle services they consume, such as Azure Synapse or Oracle Autonomous Database.

"Microsoft and Oracle have a long history of working together to support the needs of our joint customers, and this partnership is an example of how we offer customer choice and flexibility as they digitally transform with cloud technology. Oracle's decision to select Microsoft as its preferred partner deepens the relationship between our two companies and provides customers with the assurance of working with two industry leaders," said Corey Sanders, corporate vice president, Microsoft Cloud for Industry and Global Expansion.

"There's a well-known myth that you can't run real applications across two clouds. We can now dispel that myth as we supply Oracle and Microsoft customers the ability to easily test and demonstrate the value of combining Oracle databases with Azure applications. There is no need for deep skills on either of our platforms or complex configurations—anyone can use the Azure Portal to harness the power of our two clouds together," said Clay Magouyrk, executive vice president, Oracle Cloud Infrastructure.

"Multicloud takes on a whole new meaning with the launch of the Oracle Database Service for Microsoft Azure. This service, designed to provide intuitive, simple access to the Exadata Database Service and Autonomous Database to Azure users in a transparent manner, responds to the critical need of Azure and Oracle customers to apply the benefits of the latest in Oracle Database technology to their Azure workloads. This combined and interactive connection of services across public clouds sets the stage for what a multicloud experience should be, and is a bold statement about where the future of cloud is heading. It should deliver huge benefits for customers, developers, and the cloud services landscape overall," said Carl Olofson, research vice president, Data Management Software, IDC.

Familiar Experience for Azure Users Combined with an Oracle Managed Service

With the new Oracle Database Service for Microsoft Azure, in just a few clicks users can connect their Azure subscriptions to their OCI tenancy. The service automatically configures everything required to link the two cloud environments and federates Azure Active Directory identities, making it easy for Azure customers to use the service. It also provides a familiar dashboard for Oracle Database Services on OCI using Azure terminology and monitoring with Azure Application Insights.

"Many of our mission-critical workloads are running Oracle databases on-premises at massive scale. As we move these workloads to the cloud, Oracle Database Service for Azure enables us to modernize these Oracle databases to services such as Autonomous Database in OCI while leveraging Microsoft Azure for the application tier," said Jeremy Legg, chief technology officer, AT&T. Watch the video.

"Multicloud architectures enable us to choose the best cloud provider for each workload based on capabilities, performance, and price. The OCI and Azure partnership integrates the capabilities of two major cloud providers, including the Oracle Database services in OCI and Azure's application development capabilities," said Naveen Manga, chief technology officer, Marriott International. Watch the video.

"Oracle Database Service for Microsoft Azure has simplified the use of a multicloud environment for data analytics. We were able to easily ingest large volumes of data hosted by Oracle Exadata Database Service on OCI to Azure Data Factory where we are using Azure Synapse for analysis," said Jane Zhu, senior vice president and chief information officer, Corporate Operations, Veritas.

"Oracle Database Service for Microsoft Azure simplifies our multicloud approach. We're going to be able to leverage the best of Oracle databases in Azure, and we are going to be able to keep our infrastructure in Azure. This is a great opportunity to have the best of the two worlds that eases our migration to the cloud and improves the skills of our people in IT," said David Plaza, chief information officer, SGS. Watch the video.

Additional Resources

About Oracle

Oracle offers integrated suites of applications plus secure, autonomous infrastructure in the Oracle Cloud. For more information about Oracle ORCL, please visit us at oracle.com.

About Microsoft

Microsoft (Nasdaq "MSFT" @microsoft) enables digital transformation for the era of an intelligent cloud and an intelligent edge. Its mission is to empower every person and every organization on the planet to achieve more.

Trademarks

Oracle, Java, and MySQL are registered trademarks of Oracle Corporation.

Contact Info

Carolin Bachmann
Oracle PR
+1.415.622.8466
carolin.bachmann@oracle.com

Microsoft Media Relations
WE Communications for Microsoft
+1 425 638 7777
rapidresponse@we-worldwide.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/oracle-and-microsoft-announce-availability-of-oracle-database-service-for-microsoft-azure-301589773.html

SOURCE Oracle

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Ad Disclosure: The rate information is obtained by Bankrate from the listed institutions. Bankrate cannot guaranty the accuracy or availability of any rates shown above. Institutions may have different rates on their own websites than those posted on Bankrate.com. The listings that appear on this page are from companies from which this website receives compensation, which may impact how, where, and in what order products appear. This table does not include all companies or all available products.

All rates are subject to change without notice and may vary depending on location. These quotes are from banks, thrifts, and credit unions, some of whom have paid for a link to their own Web site where you can find additional information. Those with a paid link are our Advertisers. Those without a paid link are listings we obtain to Improve the consumer shopping experience and are not Advertisers. To receive the Bankrate.com rate from an Advertiser, please identify yourself as a Bankrate customer. Bank and thrift deposits are insured by the Federal Deposit Insurance Corp. Credit union deposits are insured by the National Credit Union Administration.

Consumer Satisfaction: Bankrate attempts to verify the accuracy and availability of its Advertisers' terms through its quality assurance process and requires Advertisers to agree to our Terms and Conditions and to adhere to our Quality Control Program. If you believe that you have received an inaccurate quote or are otherwise not satisfied with the services provided to you by the institution you choose, please click here.

Rate collection and criteria: Click here for more information on rate collection and criteria.

Wed, 20 Jul 2022 00:25:00 -0500 text/html https://www.benzinga.com/pressreleases/22/07/n28130951/oracle-and-microsoft-announce-availability-of-oracle-database-service-for-microsoft-azure
Killexams : Veritas Technologies Named a Leader in the 2022 Gartner® Magic Quadrant™ for Enterprise Backup and Recovery Software Solutions for the 17th Time

Veritas Technologies, a leader in multi-cloud data management, today announced it has been named a Leader in the Gartner Magic Quadrant for Enterprise Backup and Recovery Software Solutions for the 17th time.1 Veritas believes this recognition further validates the company's investment and commitment to delivering a rapid pace of innovation and the most advanced solutions to protect and recover the critical data of the world's largest enterprises.

Enterprises are facing the unparalleled challenge of managing unprecedented data growth across increasingly complex multi-cloud environments, leading to larger attack surfaces and increasing ransomware threats – one of the biggest business risks today. Veritas is uniquely positioned to address this challenge.

Veritas continues to drive innovation as it executes on its vision for delivering Autonomous Data Management, where data is protected invisibly and automatically without sacrificing human oversight. NetBackup 10 is the industry's first cloud-optimized, highly scalable data protection solution that uses AI and automation, enabling IT to shift its focus from day-to-day business operations to driving transformation. Benefits of the solution include:

  • Automated operations: Dynamic cloud autoscaling, intelligent cloud policies, and AI-based anomaly detection help to maximize efficiency and security with minimal oversight.
  • Cloud-native architecture: Veritas' rearchitected NetBackup technology stack integrates new Cloud Scale Technology to provide a unified, cloud-optimized, secure experience across on-premises, hybrid and multi-cloud environments. It combines cloud-native snapshots with elastic deduplication and lifecycle management capabilities to significantly reduce total cost of ownership.
  • Cybersecurity: NetBackup delivers a multi-layered approach to security providing unparalleled ransomware resiliency in the face of an attack, including immutable storage, malware scanning and automated, orchestrated recovery with a single click.
  • Flexibility: NetBackup provides multiple deployment options for customers delivering the flexibility to choose the ideal solution for their unique requirements and use cases. Options include software only, appliances and SaaS solutions.
  • Global reach: Veritas supports large enterprises on a global scale with a strong partner ecosystem, enabling an advanced customer experience across geographies.

Deepak Mohan, executive vice president of products at Veritas, said: "As enterprises continue to advance their multi-cloud strategies, it is now more important than ever that they deploy an Autonomous Data Management solution that automatically finds and protects data, no matter where it lives, all without human involvement to increase efficiency and reduce complexity. Veritas is continuously innovating and executing to transform the future of data management with autonomous, cloud-optimized solutions. We believe that being recognized as a Leader in the Gartner Magic Quadrant for Enterprise Backup and Recovery Software Solutions further corroborates our strategy and ongoing dedication to protecting our customers' critical data consistently and efficiently across any cloud at any scale."

A complimentary copy of the full 2022 Gartner Magic Quadrant for Enterprise Backup and Recovery Software Solutions report can be found here.

1Previous titles include Magic Quadrant and Datacenter Backup and Recovery Solutions (2020-2019), Magic Quadrant for Enterprise Backup Software and Integrated Appliances (2014-2015), Magic Quadrant for Enterprise Backup/Recovery Software (2011-2013), Enterprise Backup and Restore Magic Quadrant (2001, 2003-2005), Enterprise Backup Vendor Magic Quadrant (1999-2000). From 2005-2015, Veritas Technologies was known as Symantec.

Gartner, Magic Quadrant for Enterprise Backup and Recovery Software Solutions, Michael Hoeck, Nik Simpson, Jerry Rozeman, Jason Donham, 28 July 2022.

Gartner Disclaimer

Gartner does not endorse any vendor, product or service depicted in our research publications, and does not advise technology users to select only those vendors with the highest ratings or other designation. Gartner research publications consist of the opinions of Gartner's research organization and should not be construed as statements of fact. Gartner disclaims all warranties, expressed or implied, with respect to this research, including any warranties of merchantability or fitness for a particular purpose.

GARTNER and Magic Quadrant are registered trademarks and service mark of Gartner, Inc. and/or its affiliates in the U.S. and internationally and are used herein with permission. All rights reserved.

About Veritas

Veritas Technologies is a leader in multi-cloud data management. Over 80,000 customers—including 95% of the Fortune 100–rely on us to help ensure the protection, recoverability, and compliance of their data. Veritas has a reputation for reliability at scale, which delivers the resilience its customers need against the disruptions threatened by cyberattacks, like ransomware. No other vendor is able to match Veritas' ability to execute, with support for 800+ data sources, 100+ operating systems, 1,400+ storage targets, and 60+ clouds through a single, unified approach. Powered by our Cloud Scale Technology, Veritas is delivering today on its strategy for Autonomous Data Management that reduces operational overhead while delivering greater value. Learn more at www.veritas.com. Follow us on Twitter at @veritastechllc.

Veritas and the Veritas Logo are trademarks or registered trademarks of Veritas Technologies LLC or its affiliates in the US and other countries.

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Ad Disclosure: The rate information is obtained by Bankrate from the listed institutions. Bankrate cannot guaranty the accuracy or availability of any rates shown above. Institutions may have different rates on their own websites than those posted on Bankrate.com. The listings that appear on this page are from companies from which this website receives compensation, which may impact how, where, and in what order products appear. This table does not include all companies or all available products.

All rates are subject to change without notice and may vary depending on location. These quotes are from banks, thrifts, and credit unions, some of whom have paid for a link to their own Web site where you can find additional information. Those with a paid link are our Advertisers. Those without a paid link are listings we obtain to Improve the consumer shopping experience and are not Advertisers. To receive the Bankrate.com rate from an Advertiser, please identify yourself as a Bankrate customer. Bank and thrift deposits are insured by the Federal Deposit Insurance Corp. Credit union deposits are insured by the National Credit Union Administration.

Consumer Satisfaction: Bankrate attempts to verify the accuracy and availability of its Advertisers' terms through its quality assurance process and requires Advertisers to agree to our Terms and Conditions and to adhere to our Quality Control Program. If you believe that you have received an inaccurate quote or are otherwise not satisfied with the services provided to you by the institution you choose, please click here.

Rate collection and criteria: Click here for more information on rate collection and criteria.

Wed, 03 Aug 2022 03:15:00 -0500 text/html https://www.benzinga.com/pressreleases/22/08/b28334730/veritas-technologies-named-a-leader-in-the-2022-gartner-magic-quadrant-for-enterprise-backup-and-r
Killexams : Offshore News

CorPower Ocean unveiled the CorPower C4, its first commercial scale Wave Energy Converter (WEC) and CorPack clusters, which the company contends will provide the building blocks for utility scale wave farms.Ultimately, the new CorPower C4 device will form part of a four-system wave array, off the coast of Aguçadoura, Portugal, creating a grid-connected wave farms.“This has been a decade-long development, with significant strides in the last few years to industrialise and optimize our wave energy technology," said Patrik Möller, Co-founder & CEO. "Following today’s launch, we aim to propel wave energy into the future green energy mix as a bankable technology through the HiWave-5 Project.”The CorPower C4…

Thu, 04 Aug 2022 12:00:00 -0500 en text/html https://www.marinelink.com/news/maritime/offshore
Killexams : Evaluating Web-Based Direct-to-Consumer Genetic Tests for Cancer Susceptibility

Falling costs of genetic testing in combination with growing public interest in personal genomics has driven the expansion of direct-to-consumer (DTC) genetic testing. Today’s market encompasses a broad range of offerings, from tests that pair users with wines to tests that reveal serious disease risks.1 This review focuses on one area of the rapidly expanding DTC market—genetic testing for cancer susceptibility. Within this space, DTC offerings vary considerably in size and scope. The narrowest is a test that screens for three specific mutations in two genes and the broadest is a whole-genome sequencing service that analyzes dozens of genes for mutations that could affect cancer risk.

Traditionally, DTC genetic tests were advertised—and sold—to consumers without involving a health care professional; however, in recent years, a new model of testing has come to dominate the market. In this model, tests are advertised to consumers but ordered by licensed physicians.2-5 A number of companies even allow consumers to choose between having tests ordered by their own physician or by a company-provided independent physician.

In both the academic literature and the popular media, there is a lack of clarity about which genetic tests count as DTC offerings.6 This uncertainty, as Hogarth et al7 explain, stems from ambiguity about the meaning of direct-to-consumer, a term that “has been used variously to refer to both advertising and sale of genetic tests.” According to the US National Institutes of Health (NIH), DTC genetic tests “are marketed directly to customers via television, print advertisements, or the Internet, and . . . can be bought online or in stores.”8(p163) Under this expansive definition, tests that are advertised to consumers but ordered by licensed physicians—often referred to as the hybrid model—fall within the ambit of DTC genetic testing.2,5

CONTEXT

  • Key Objective

  • To provide an overview of available direct-to-consumer (DTC) genetic tests for cancer susceptibility and to identify six aspects of the testing process that could affect consumers’ ability to make informed decisions about testing and interpret their results.

  • Knowledge Generated

  • Recent years have seen DTC genetic testing for cancer susceptibility change dramatically. Specifically, a new model now dominates the market where tests are advertised to consumers but ordered by physicians. Moreover, many of today’s tests are distinguished from earlier DTC offerings for cancer susceptibility by their scope and potential clinical significance. This review provides a comprehensive overview of available DTC genetic tests for cancer susceptibility and identifies aspects of the DTC testing process that could affect consumers’ ability to make informed decisions about testing and understand their results. Given how the DTC genetic testing market for cancer susceptibility has changed in recent years, it is essential that health care professionals and researchers working in this space appreciate both the range of tests being offered and the challenges that consumers may face as they navigate this evolving landscape.

  • Relevance

  • On the basis of our review of companies’ Web sites, consumers would benefit from more information about certain aspects of the testing process. Providing this information would help consumers make informed decisions about whether to use a particular DTC genetic testing service and, should they choose to pursue testing, understand the implications and limitations of their results.

Other than the shift toward physician-ordered testing, many of today’s tests are distinguished from their predecessors by their scope and potential clinical significance. Previously, in the mid-to-late 2000s, most DTC tests used single-nucleotide variation profiling to assess cancer risk, a process that involves screening a DNA sample for single-nucleotide polymorphisms (SNPs)—single base-pair differences that occur at specific positions in the genome—that may affect cancer risk.9,10 Single-nucleotide variation profiling, however, tends to have low predictive value for disease risk and limited usefulness in improving health outcomes (ie, clinical utility).

Today’s DTC companies have largely moved away from using single-nucleotide variation profiling. Instead, they tend to analyze specific genes for mutations that increase cancer risk. Yet this change has not eliminated uncertainty in cancer susceptibility genetic testing. For many of the genes included in larger tests, a positive result may be associated with uncertain risk estimates and/or unclear medical management strategies.11,12

Given how the DTC genetic testing market for cancer susceptibility has changed in recent years, it is essential that health care professionals and researchers working in this space appreciate both the range of tests being offered and the challenges that consumers may face as they navigate this evolving landscape. Part I of this paper provides an overview of available DTC genetic tests for cancer susceptibility as of July 2019. For each test, we discuss cost; who orders it; whether variants of uncertain significance (VUS) are returned; availability of genetic counseling; intended users; whether consumers are recontacted about variant reclassifications; whether the test is characterized by the company as being diagnostic, actionable, and clinically valid; molecular technique used to analyze DNA; and whether the test is Clinical Laboratory Improvement Amendments (CLIA) certified and College of American Pathologists (CAP) accredited.

In Part II, we identify six aspects of the testing process that we believe could affect consumers’ ability to make informed decisions about testing and understand the implications—and limitations—of their results.13 These are: how companies use certain terms (eg, medical grade or clinical grade); how companies use consumers’ health information during the ordering process; the extent of genetic counseling provided by companies; companies’ procedures for returning results; the role of company-provided ordering physicians; and companies’ procedures for communicating variant reclassifications. On the basis of our review of companies’ Web sites, we believe that consumers would benefit from more information about these aspects of testing.

Here we describe the array of DTC genetic tests for cancer susceptibility that were on the market as of July 2019 (Table 1). Given the Internet-based nature of DTC genetic testing, today’s consumers primarily receive and interact with DTC companies’ offerings through their Web sites. Thus, to better capture the information that consumers are likely to access when deciding whether to use a test, we only include information about testing services that is, or was, available on companies’ Web sites. It is worth noting that some companies do not explicitly define the terms diagnostic, actionable, or clinically valid. Whereas we describe how each company characterizes these terms and indicate when definitions are absent, inasmuch as our objective is to convey what companies report on their Web sites, we do not evaluate the accuracy of their claims.14

Table

TABLE 1. Direct-to-Consumer Genetic Tests for Cancer Susceptibility

23andMe

In 2013, the US Food and Drug Administration (FDA) issued a warning letter to 23andMe (Sunnyvale, CA) ordering the company to discontinue marketing its Personal Genome Service, which included reports for several hundred diseases and conditions, an SNP-based risk score for breast cancer, and a limited BRCA1/BRCA2 test.15 According to the FDA, 23andMe had failed to demonstrate that its service could correctly identify genetic disease risks, made misleading claims about the health benefits of tests, and failed to comply with the premarket review process for medical devices.16

Since that time, 23andMe has substantially revised its services. In March 2018, the FDA authorized 23andMe to market a BRCA test that screens for three specific BRCA1/BRCA2 variants, making it the first FDA-authorized DTC genetic test to report on cancer risk.17,18 Although there are more than 1,000 known BRCA1/BRCA2 mutations that are associated with an increased risk of breast and ovarian cancer, 23andMe’s test only screens for three founder mutations—two in the BRCA1 gene (BRCA1 c.68_69delAG and BRCA1 c.5266dupC) and one in the BRCA2 gene (BRCA2 c.5946delT)—that are found almost exclusively in individuals of Ashkenazi Jewish descent.17 The test, therefore, is unlikely to be useful to individuals from other ethnic backgrounds.19,20 As 23andMe acknowledges, its BRCA screen is not comprehensive and does not rule out the possibility that an individual carries one of the many BRCA1/BRCA2 mutations not covered by its report.21

In January 2019, 23andMe received FDA clearance to expand its cancer susceptibility testing to report on two MUTYH genetic mutations that are implicated in MUTYH-associated polyposis, an autosomal recessive hereditary colorectal cancer syndrome.22 The two variants that are included in the test—p.Y179C and p.G396D—are the most common pathogenic MUTYH mutations in individuals of northern European descent, although there are more than 100 pathogenic MUTYH variants.23 In the general northern European, Australian, and US population, the heterozygous carrier frequency for a pathogenic MUTYH variant is 1% to 2%.2 Individuals with a single MUTYH mutation are thought to have a slightly increased risk of colorectal cancer relative to the general population lifetime risk—approximately 4%.25-27 In contrast, individuals carrying mutations in both MUTYH alleles have a much higher cumulative risk of colorectal cancer—approximately 80% by age 70.28

23andMe’s BRCA report is included with its Health + Ancestry Service.29 Excluding special offers, the service costs $199. Consumers order their own tests and receive their results through an online account. If a consumer does not wish to view his or her BRCA result, they can opt to exclude it from the report. Although the company does not provide genetic counseling, consumers are encouraged to consult with a genetic counselor before and after testing. 23andMe uses genotyping to analyze DNA. The company states that its BRCA test meets FDA requirements for clinical validity, which it defines as “the degree to which a test accurately identifies or predicts a disease of interest.”30 23andMe maintains that its BRCA test “is not intended to diagnose any disease and does not describe a person’s overall risk of developing any type of cancer.”22 It also maintains that the test is not medically actionable and that “[r]esults should be confirmed in a clinical setting before taking any medical action.”22 All DNA samples are processed in CLIA-certified and CAP-accredited laboratories.

Veritas Genetics

Veritas (Santa Clara, CA) offers a whole-genome sequencing service called myGenome Standard that costs $599. For an additional $1,000, consumers can upgrade to myGenome Premium, which includes more diseases and carrier conditions. myGenome (standard and premium) can be ordered by the consumer’s own provider or, for an additional $129, by an independent physician affiliated with the telegenomics company Genome Medical. When the results are ready, Veritas notifies the consumer and the ordering provider, both of whom can then access the report through Veritas’ Web portal. If interested, consumers can pay an additional $99 to receive their raw data.

For myGenome (standard and premium), pathogenic and likely pathogenic results are reported, and benign, likely benign, and VUS results are not typically returned. Veritas does not state whether it will contact the ordering provider or the consumer about variant reclassifications. Through Genome Medical, Veritas offers a complimentary 30-minute return of results genetic counseling session for clinically actionable findings. Consumers can also pay $299 for Comprehensive Genetic Counseling, which includes access to pretest counseling and a 60-minute post-test session to review results.

According to Veritas, its service is intended to be a screening test for healthy individuals; however, myGenome is not meant to be diagnostic because “there is a chance that some of the variants that are associated with health conditions or disease risk could be missed.”31 As such, the test “should not be used to diagnose a known or suspected heritable disease in [the consumer] or [the consumer’s family].”32 Veritas does not state whether myGenome is a clinically valid test. It does, however, characterize myGenome as providing information that may “affect [the consumer’s] health and [is] actionable, be it with changes in diet and activity level, medical screenings, or enhanced vigilance.”33 Nevertheless, it is not clear that Veritas’ findings, at least by themselves, are intended to inform clinical care.34 This interpretation is supported by the company’s informed consent document, which states that “all variants considered clinically relevant in [the consumer’s] report should be confirmed with secondary testing before changes to [the consumer’s] healthcare are made.”32 Veritas uses next-generation sequencing to analyze DNA. The company’s US laboratory is CLIA certified and CAP accredited.

Invitae Corporation

Invitae (San Francisco, CA) offers a cancer susceptibility panel—Invitae Cancer Screen—that consists of 61 genes associated with 10 types of cancer (breast, colorectal, gastric, ovarian, pancreatic, prostate, renal cell, thyroid, uterine, and cutaneous melanoma). In addition, Invitae offers cancer susceptibility testing as part of its Genetic Health Screen, which consists of a 147-gene panel that also analyzes genes related to cardiac diseases and other inherited conditions. Neither test is intended to be diagnostic; both are considered proactive services that are intended for healthy adults without a strong personal or family history of cancer.

Invitae’s Cancer Screen and Genetic Health Screen cost $250 and $350, respectively, and can be ordered by the consumer’s own provider or by a company-provided physician. The ordering provider is notified via e-mail when the results are ready and receives a written report. Consumers who have their test ordered by an independent physician receive an e-mail when the results are ready, at which time they can review their results and schedule an appointment with one of Invitae’s genetic counselors. Post-test genetic counseling is available at no additional cost.

Invitae uses next-generation sequencing and does not report VUS findings for proactive tests. However, if a VUS is reclassified to likely pathogenic or pathogenic, Invitae will inform the ordering physician and issue an updated report. Invitae does not say whether it will contact the ordering physician and issue an amended report for other variant reclassifications. The company also does not state whether either proactive test is clinically valid, although it does provide links to validation studies.35 Regarding actionability, Invitae maintains that consumers can “take action based on [their] results” and “work with [their] provider to consider: increased or earlier screenings, lifestyle modifications, and early intervention to prevent the onset of disease.”36 Invitae’s laboratory is CLIA certified and CAP accredited.

Color Genomics

Color Genomics (Burlingame, CA) offers a test called Color Extended that analyzes genes related to cancer, cardiac disease, and medication response. The test costs $258.95 and includes 30 cancer predisposition genes associated with eight types of cancer (breast, ovarian, uterine, colorectal, melanoma, pancreatic, stomach, and prostate). Color Extended can be ordered by either the consumer’s own provider or by a company-provided independent physician at no additional charge. If the consumer’s own provider orders the test, the provider can choose whether the results are released to the consumer as soon as they are ready or after a delay. For tests that are ordered by an independent physician, information about the process for returning results is not available on the company’s Web site. Consumers who wish to discuss their results can access complimentary genetic counseling.

Color uses next-generation sequencing and reports VUS findings. If a VUS result is reclassified, Color will attempt to recontact the consumer. The company does not state whether Color Extended is a clinically valid test in its entirety. However, there is a section on the Web site where Color discusses the clinical validity of its tests with respect to certain conditions.37 Color Extended is described as being actionable, meaning that the consumer can “work with [their] healthcare provider to create a personalized screening and prevention plan, designed to reduce [their] risk of developing cancer.”38 Color maintains that its test is not diagnostic because “[p]ositive results do not necessarily mean that [the consumer] [has] that hereditary disorder or that [the consumer] will develop the disorder in [their] lifetime” and “[n]egative results do not eliminate [the consumer’s] risk of developing a disorder, and do not guarantee that [the consumer] will be healthy or will never develop any of the disorders that Color tests for.”39 Color’s laboratory is CLIA certified and CAP accredited.

Helix

Helix (San Carlos, CA) offers two tests—GenePrism and Prostate Cancer Genetic Risk Score—that evaluate cancer susceptibility. Whereas both tests are sold by Helix, GenePrism is administered by PerkinElmer Genomics, and Prostate Cancer Genetic Risk Score is administered by NorthShore University HealthSystem. The tests can only be ordered by a physician who is affiliated with the relevant partner company.

GenePrism analyzes the 59 genes included in the American College of Medical Genetics and Genomics’ list of actionable genes, of which 26 are associated with an increased risk of cancer.40 The test costs $299.99, including a $30 fee that covers the ordering physician and genetic counseling services. The test is “intended to provide proactive health insights for those who do not have a significant family history associated with the health conditions that it includes.”41 The consumer is notified by e-mail when the results are ready to be accessed through the GenePrism Web site. Helix does not explicitly state whether the test is clinically valid. GenePrism is not a diagnostic test and “is not intended to diagnose any medical conditions” and “will not tell you if you currently have one of the conditions covered by the test, or if you definitely will or will not develop the condition in the future.”41 The test does not report VUS results. Helix describes the test as actionable, which, according to the company, means that “if [the consumer] learn[s] of a genetic risk from the test, [the consumer’s] risk is significantly increased over the general population, and there are actions [the consumer] or [the consumer’s] doctor can take to reduce [the consumer’s] risks based on established medical recommendations.”41 Helix does not explain its procedures for recontacting consumers about variant reclassifications, although the company does maintain that “[r]esults may change as research continues to allow us to better interpret what these and other genes mean for health.”41

Prostate Cancer Genetic Risk Score is an outlier among DTC cancer susceptibility tests. Unlike other tests that focus on single-gene mutations, Helix’s test provides a polygenic risk score based on an analysis of numerous SNPs that affect prostate cancer. The test costs $239.99, which includes a $40.00 fee that covers the ordering physician and genetic counseling services. Helix does not state whether the test is intended for individuals with a personal and/or family history of prostate cancer. Results are returned through secure e-mail. Helix maintains that the test is not a diagnostic product because “[a]n estimate of [the consumer’s] risk does not determine if [the consumer] will or will not get prostate cancer.”42 Helix does not state whether the test is clinically valid or whether results are medically actionable.

Helix uses next-generation sequencing to analyze DNA. For both GenePrism and Prostate Cancer Genetic Risk Score, genetic counseling is available through Genome Medical at no additional charge. Helix’s laboratory is CLIA certified and CAP accredited.

Meaning of Terms

In describing their offerings, several companies use terms that they do not clearly define. For example, Invitae characterizes its proactive tests as medical grade and diagnostic grade. Except to say that its proactive tests “offer the same clinical quality as a diagnostic test,” the company does not explicitly define either of these terms.43 Similarly, Color characterizes its offering as an “affordable clinical-grade test,” but does not specify what the term clinical grade means. Of note, despite describing these tests as medical, diagnostic, or clinical grade, both Invitae and Color maintain that their services are not intended to be diagnostic.39,43 Consumers who are unclear about the meanings of these terms, none of which are scientific or medical designations, may struggle to understand why a test that is marketed as medical-, diagnostic-, or clinical grade should not be used in a diagnostic capacity.

In addition, given that tests are often characterized as being medical, diagnostic, or clinical grade, consumers may wonder whether their results could expose them to potential insurance discrimination. According to the Genetic Nondiscrimination Act (GINA), it is illegal for US health insurance providers to use genetic information, including from DTC tests, to deny coverage or increase premiums. GINA, however, does not apply when an employer has fewer than 15 employees or to other forms of insurance (eg, disability insurance, long-term care insurance, and/or life insurance).44 Although all of the companies seem to provide some information on their Web sites about genetic discrimination, discussions about how consumers’ results could affect their access to different types of insurance is often covered during pretest counseling, which may be lacking in the DTC setting.

Companies could also be more transparent about whether their tests can accurately predict an individual’s risk of developing a particular disease—that is, whether they are clinically valid. Most DTC cancer susceptibility genetic tests analyze an array of genes that encompass a wide range of risk estimates. Whereas some of the genes included in these tests have well-established risk estimates, not all do. For example, Color and Veritas’ tests include the MITF gene.45,46 Although MITF mutations are suspected to increase the risk of melanoma and renal carcinoma, the extent to which a mutation carrier’s risk is elevated remains unclear.45,47 Overall, consumers might benefit from greater clarity about which genes in a test are considered clinically valid. Providing this information in a transparent and accessible manner could help consumers decide whether to pursue a test that may include genes with low predictive value for cancer risk.

Use of Consumers’ Health Information

Companies with testing services that can be ordered by a company-provided physician often ask consumers to answer a set of questions about their personal and family health history; however, it is not always clear how ordering physicians use this information. For example, Veritas maintains that consumers’ responses to these questions “are necessary to sequence [their] DNA and also helps [Veritas] better interpret [their] results.”48 Nevertheless, Veritas does not clarify how this information factors into the ordering process. As consumers consider whether to purchase a test, they may be interested in learning how their health information will be used. In particular, they might want to know whether the physician will follow up to discuss their health history before ordering testing. Consumers might also wonder whether company-provided physicians ever decline to order testing and, if so, for what reasons.

Genetic Counseling

Although all of the companies that offer physician-ordered DTC genetic tests seem to provide genetic counseling in some capacity, the extent, timing, and cost of these services is sometimes unclear. For example, Invitae maintains that “[o]ur team of board-certified genetic counselors is available on demand by phone during business hours to assist you with general questions about genetic testing and your results.”49 What remains unclear (for Invitae and some of the other companies) is the extent to which pretest counseling is comprehensive and individualized. In the clinical setting, pretest counseling is widely regarded as an important part of obtaining informed consent to testing.50,51 Companies could therefore help consumers make informed choices about whether to pursue DTC testing by including more information on their Web sites about pretest counseling.

Currently, companies differ in terms of how they provide genetic counseling. Helix, for example, outsources its genetic counseling to Genome Medical, which is a distinct corporate entity from Helix.41 Other companies, such as Invitae, offer in-house counseling that includes pretest counseling.49 This arrangement raises potential ethical concerns about whether a conflict of interest arises when companies provide pretest counseling services for their own tests.52,53

Procedures for Returning Results

Most of the companies that offer tests through the physician-ordered model do not include a detailed description of their process for returning results. On the basis of the companies’ online materials, it may not be clear whether procedures vary depending on the clinical significance of consumers’ results. Are positive and VUS results disclosed over the phone by a genetic counselor, while negative results are delivered through an online portal? Again, providing more information could help consumers make informed decisions about whether they are comfortable with a company’s model for returning results.

Role of Company-Provided Physicians

For some of the companies that offer company-provided independent physicians, it is unclear what role, if any, these physicians play beyond simply ordering tests. It is also not clear how companies conceive of the relationship between consumers and these physicians, some of whom may belong to an external physician network or separate company.54 For example, Helix states that the company “will share [the consumer’s] contact information and health history with PerkinElmer Genomics so a physician they designate can review and make sure this product is right for [the consumer].”41 Consumers may wonder whether they can contact the ordering physician with additional questions about the test or their results. Notably, will the ordering physician assume responsibility for a consumer’s follow-up care or refer the consumer to another provider? As of now, these questions are not easily answerable from companies’ online materials.

Variant Reclassification

As scientific understanding of variant pathogenicity evolves, genetic test results may be amended. Some changes could have significant clinical implications for disease risk and medical management (eg, a VUS that is upgraded to pathogenic). Nevertheless, information about companies’ procedures for handling amended results may not be readily available. Color’s Informed Consent, for instance, lacks specific information about how the company manages variant reclassification beyond stating that it may “at its sole discretion, amend or modify [the consumer’s] Test report” and will “attempt to notify (the consumer) of any material amendments or modifications.”39 Some companies, however, do not provide any information about variant reclassification. Helix’s informed consent, for instance, notes that “future information may change your results,” but does not specify whether the company monitors for variant changes or notify consumers about them.55 Given the potential clinical significance of variant reclassifications, consumers could benefit from more information about companies’ procedures for tracking variant changes and sharing amended results.

In conclusion, genetic testing for cancer susceptibility, once limited to the clinical setting, is now widely available through Web-based DTC genetic testing companies. To better understand whether test takers are knowledgeable about companies’ testing procedures, there is an urgent need to collect and study consumer outcome data.13 As the DTC market continues to evolve, outcome data should inform companies’ products and practices to ensure that consumers are equipped to make informed decisions throughout the testing process and understand their results.

1. Vinome: Home. https://vinome.com/ Google Scholar 2. Allyse MA, Robinson DH, Ferber MJ, et al: Direct-to-consumer testing 2.0: Emerging models of direct-to-consumer genetic testing. Mayo Clin Proc 93:113-120, 2018 Crossref, MedlineGoogle Scholar 3. Roberts JS, Ostergren J: Direct-to-consumer genetic testing and personal genomics services: A review of recent empirical studies. Curr Genet Med Rep 1:182-200, 2013 Crossref, MedlineGoogle Scholar 4. Howard HC, Borry P: Is there a doctor in the house?: The presence of physicians in the direct-to-consumer genetic testing context. J Community Genet 3:105-112, 2012 Crossref, MedlineGoogle Scholar 5. Phillips KA, Trosman JR, Douglas MP: Emergence of hybrid models of genetic testing beyond direct-to-consumer or traditional labs. JAMA 321:2403-2404, 2019 Crossref, MedlineGoogle Scholar 6. Chokoshvili D, Vears DF, Borry P: Growing complexity of (expanded) carrier screening: Direct-to-consumer, physician-mediated, and clinic-based offers. Best Pract Res Clin Obstet Gynaecol 44:57-67, 2017 Crossref, MedlineGoogle Scholar 7. Hogarth S, Javitt G, Melzer D: The current landscape for direct-to-consumer genetic testing: Legal, ethical, and policy issues. Annu Rev Genomics Hum Genet 9:161-182, 2008 Crossref, MedlineGoogle Scholar 8. National Institutes of Health: Genetics Home Reference: What is direct-to-consumer genetic testing? https://ghr.nlm.nih.gov/primer/dtcgenetictesting/directtoconsumer Google Scholar 9. Bellcross CA, Page PZ, Meaney-Delman D: Direct-to-consumer personal genome testing and cancer risk prediction. Cancer J 18:293-302, 2012 Crossref, MedlineGoogle Scholar 10. Kutz G: Direct-to-consumer genetic tests: Misleading test results are further complicated by deceptive marketing and other questionable practices. Washington DC, US Government Accountability Office, 2010 Google Scholar 11. Domchek SM, Bradbury A, Garber JE, et al: Multiplex genetic testing for cancer susceptibility: Out on the high wire without a net? J Clin Oncol 31:1267-1270, 2013 LinkGoogle Scholar 12. Kilbride MK, Domchek SM, Bradbury AR: Ethical implications of direct-to-consumer hereditary cancer tests. JAMA Oncol 4:1327-1328, 2018 Crossref, MedlineGoogle Scholar 13. Spector-Bagdady K: Reconceptualizing consent for direct-to-consumer health services. Am J Law Med 41:568-616, 2015 Crossref, MedlineGoogle Scholar 14. US Food and Drug Administration: Frequently asked questions about CDER. https://www.fda.gov/about-fda/center-drug-evaluation-and-research-cder/frequently-asked-questions-about-cder#4 Google Scholar 15. 23andMe: What you can expect. https://web.archive.org/web/20131127233338/https://www.23andme.com/health/all/ Google Scholar 16. US Food and Drug Administration: Warning letter. https://wayback.archive-it.org/7993/20170111084101/http://www.fda.gov/ICECI/EnforcementActions/WarningLetters/2013/ucm376296.htm Google Scholar 17. US Food and Drug Administration: FDA authorizes, with special controls, direct-to-consumer test that reports three mutations in the BRCA breast cancer genes. https://www.fda.gov/newsevents/newsroom/pressannouncements/ucm599560.htm Google Scholar 18. Francke U, Dijamco C, Kiefer AK, et al: Dealing with the unexpected: Consumer responses to direct-access BRCA mutation testing. PeerJ 1:e8, 2013 Crossref, MedlineGoogle Scholar 19. Gill J, Obley AJ, Prasad V: Direct-to-consumer genetic testing: The implications of the US FDA’s first marketing authorization for BRCA mutation testing. JAMA 319:2377-2378, 2018 Crossref, MedlineGoogle Scholar 20. Artin MG, Stiles D, Kiryluk K, et al: Cases in precision medicine: When patients present with direct-to-consumer genetic test results. Ann Intern Med 170:643-650, 2019 Crossref, MedlineGoogle Scholar 21. 23andMe: Do you speak BRCA? https://www.23andme.com/brca/ Google Scholar 22. 23andMe: 23andMe receives FDA clearance for genetic health risk report that looks at a hereditary colorectal cancer syndrome. https://blog.23andme.com/health-traits/23andme-receives-fda-clearance-for-genetic-health-risk-report-that-looks-at-a-hereditary-colorectal-cancer-syndrome/ Google Scholar 23. US Food and Drug Administration: 510(k) substantial equivalence determination decision summary. https://www.accessdata.fda.gov/cdrh_docs/reviews/K182784.pdf Google Scholar 24. National Institutes of Health: Polyposis MUTYH. https://www.ncbi.nlm.nih.gov/books/NBK107219/#maps.Prevalence Google Scholar 25. National Cancer Institute: Cancer stat facts: Colorectal cancer. https://seer.cancer.gov/statfacts/html/colorect.html Google Scholar 26. Sampson JR, Jones N: MUTYH-associated polyposis. Best Pract Res Clin Gastroenterol 23:209-218, 2009 Crossref, MedlineGoogle Scholar 27. Win AK, Dowty JG, Cleary SP, et al: Risk of colorectal cancer for carriers of mutations in MUTYH, with and without a family history of cancer. Gastroenterology 146:1208-1211.e1201-1205, 2014 Crossref, MedlineGoogle Scholar 28. Win AK, Cleary SP, Dowty JG, et al: Cancer risks for monoallelic MUTYH mutation carriers with a family history of colorectal cancer. Int J Cancer 129:2256-2262, 2011 Crossref, MedlineGoogle Scholar 29. 23andMe: Health + ancestry. https://www.23andme.com/dna-health-ancestry/ Google Scholar 30. 23andMe: Understanding our scientific process. https://medical.23andme.com/about-our-test/ Google Scholar 31. Veritas Genetics: Test limitations. https://www.veritasgenetics.com/sites/default/files/media/documents/ProductOnePager_myGenome_TestLimitations_Final.pdf Google Scholar 32. Veritas Genetics: Informed consent form. https://www.veritasgenetics.com/sites/default/files/media/documents/mg.icP_.1018v4.1.pdf Google Scholar 33. Veritas Genetics: Get the most comprehensive genetic testing service there is. https://www.veritasgenetics.com/myGenome Google Scholar 34. Veritas: myGenome: Frequently asked questions. https://www.veritasgenetics.com/sites/default/files/media/documents/ProductOnePager_myGenome_FAQs_V1_12.04.18.pdf Google Scholar 35. Invitae: Leading with science. https://www.invitae.com/en/validation-studies/ Google Scholar 36. Invitae: Proactive genetic testing. https://www.invitae.com/en/individuals/proactive-testing/ Google Scholar 37. Color: Testing for CDC tier 1 genomic conditions. https://cdn2.hubspot.net/hubfs/3989189/Color%20Population%20Health%20Dossier.pdf?__hssc=19492199.1.1544137941126&__hstc=19492199.dd083e937d69ddfe9539ad39e60ac673.1540603747733.1544130266596.1544137941126.39&__hsfp=3043820372&hsCtaTracking=dd024757-074d-4e51-93aa-6d28feadbb0e%7C99b388e1-993b-43e9-9f98-48687160dff3 Google Scholar 38. Color: Hereditary cancer. https://www.color.com/learn/can-cancer-be-inherited Google Scholar 39. Color: Informed consent. https://www.color.com/informed-consent Google Scholar 40. Kalia SS, Adelman K, Bale SJ, et al. Recommendations for reporting of secondary findings in clinical exome and genome sequencing, 2016 update (ACMG SF v2.0): a policy statement of the American College of Medical Genetics and Genomics. Genet Med 19:249-255, 2017 Crossref, MedlineGoogle Scholar 41. Helix: GenePrism: Actionable insights. https://www.helix.com/products/geneprism-actionable-insights Google Scholar 42. Helix. Prostate cancer genetic risk score. https://www.helix.com/products/prostate-cancer-genetic-risk-score Google Scholar 43. Invitae: How is this type of testing different from a diagnostic genetic test? https://support.invitae.com/hc/en-us/articles/115007883908-How-is-this-type-of-testing-different-from-a-diagnostic-genetic-test- Google Scholar 44. National Institutes of Health: Can the results of direct-to-consumer genetic testing affect my ability to get insurance? https://ghr.nlm.nih.gov/primer/dtcgenetictesting/dtcinsurancerisk Google Scholar 45. Color; MITF. https://static.getcolor.com/pdfs/gene/Color_MITF_gene_information.pdf Google Scholar 46. Veritas: myGenome standard/premium gene-disease list. https://www.veritasgenetics.com/sites/default/files/media/documents/VG_myGenome_Gene-Disease-List_V1_FINAL_Consumer_05.13.2019.pdf Google Scholar 47. Bertolotto C, Lesueur F, Giuliano S, et al: A SUMOylation-defective MITF germline mutation predisposes to melanoma and renal carcinoma. Nature 480:94-98, 2011 [Erratum: Nature 531:126, 2016] Crossref, MedlineGoogle Scholar 48. Veritas: Let’s get started. https://secure.veritasgenetics.com/checkout/67308 Google Scholar 49. Invitae: Genetic counseling resources at Invitae. https://www.invitae.com/en/individuals/genetic-counseling/ Google Scholar 50. American Society of Clinical Oncology: Genetic counseling: An indispensable step in the genetic testing process. J Oncol Pract 4:96-98, 2008 LinkGoogle Scholar 51. American Society of Clinical Oncology: ASCO releases updated policy statement on genetic and genomic testing for cancer susceptibility. https://www.asco.org/about-asco/press-center/news-releases/asco-releases-updated-policy-statement-genetic-and-genomic Google Scholar 52. Pollack A: The ethics of advice: Conflicts seen when genetic counselors work for test companies. The New York Times 2012;B1 Google Scholar 53. Committee on Ethics, American College of Obstetricians and Gynecologists and Committee on Genetics, American College of Obstetricians and Gynecologists: ACOG committee opinion No. 410: Ethical issues in genetic testing. Obstet Gynecol 111:1495-1502, 2008 Crossref, MedlineGoogle Scholar 54. Marietta C, McGuire AL: Currents in contemporary ethics. Direct-to-consumer genetic testing: Is it the practice of medicine? J Law Med Ethics 37:369-374, 2009 Crossref, MedlineGoogle Scholar 55. Helix: PerkinElmer GenePrism: Actionable insights informed consent. https://geneprism.helix.com/product-consent Google Scholar
Fri, 14 Aug 2020 17:22:00 -0500 en text/html https://ascopubs.org/doi/full/10.1200/PO.19.00317
Killexams : 8-K: NOVAGOLD RESOURCES INC

The MarketWatch News Department was not involved in the creation of this content.

(EDGAR Online via COMTEX) -- 0001173420 false 0001173420 2022-07-28 2022-07-28 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

                            NOVAGOLD RESOURCES INC.
             (Exact Name of Registrant as Specified in Its Charter)

British Columbia 001-31913 N/A (State of Incorporation) (Commission File Number) (I.R.S. Employer Identification)

          201 South Main Street, Suite 400, Salt Lake City, Utah 84111
              (Address of principal executive offices) (Zip Code)
                                 (801) 639-0511
              (Registrant's Telephone Number, Including Area Code)
                                      N/A

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 ? Written communications pursuant to Rule 425 under the Securities Act (17 CFR
                                    230.425)
  ? Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
                                  240.14a -12)
 ? Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange
                           Act (17 CFR 240.14d -2(b))
 ? Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange
                           Act (17 CFR 240.13e -4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class Trading Symbol(s) Name of each exchange on which registered
   Common Shares           NG                       NYSE American
                                               Toronto Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (240.12b-2).

                                                       Emerging growth company ?

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ?

Item 7.01 Regulation FD

On July 28, 2022, NOVAGOLD RESOURCES INC. ("NOVAGOLD") issued a joint press release with Donlin Gold LLC and Barrick Gold Corporation ("Barrick") reporting assay results from a drill program that NOVAGOLD and Barrick, co-owners of Donlin Gold LLC, commenced in 2022 to validate recent geological and resource modeling controls developed by the co-owners at the Donlin Gold project. A copy of the press release is furnished as Exhibit 99.1 to this report and incorporated herein by reference.

The information contained in the press release attached hereto is being furnished and shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liability of that section, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

Item 9.01 Financial Statements and Exhibits

(d) Exhibits

Exhibit Number Description
  99.1           Press release dated July 28, 2022 issued by NOVAGOLD RESOURCES INC.
               entitled "Donlin Gold Reports Excellent Initial 2022 Drill Program
               Results Yielding Encouraging Assays With More High-Grade Gold
               Intercepts Coupled With Important Grade Continuity."
104            Cover Page Interactive Data File - The cover page interactive data
               file does not appear in the Interactive Data File because its XBRL
               tags are embedded within the Inline XBRL document.
                                   SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: July 28, 2022 NOVAGOLD RESOURCES INC.

                     By:  /s/ Gregory A. Lang
                          Gregory A. Lang
                          President and Chief Executive Officer
                                                                    Exhibit 99.1
                               [[Image Removed]]

DONLIN GOLD REPORTS EXCELLENT INITIAL 2022 DRILL PROGRAM RESULTS

 YIELDING ENCOURAGING ASSAYS WITH MORE HIGH-GRADE GOLD INTERCEPTS COUPLED WITH
                           IMPORTANT GRADE CONTINUITY

July 28, 2022 - Anchorage, AK - Donlin Gold LLC ("Donlin Gold"), owned 50/50 by Barrick Gold Corporation ("Barrick") (TSX: ABX) (NYSE: GOLD) and NOVAGOLD RESOURCES INC. ("NOVAGOLD") (TSX, NYSE American: NG), is pleased to report the initial assay results for the 2022 drill program.

[[Image Removed]] The drill program is progressing ahead of schedule with 26,800
                  meters of the originally planned 34,000-meter drill program
                  completed to date, and assay results received from
                  approximately 9,870 meters of drilling. The results support the
                  recent modelling concepts, and strategic mine planning work.
[[Image Removed]] The site crew (150 employees, contractors, and student
                  interns), a majority of which are local hires representing 24
                  Yukon-Kuskokwim (Y-K) communities in Alaska, are working on a
                  two-week rotation schedule and continue to advance project
                  activities at a good pace.
[[Image Removed]] With the largest budget in more than a decade, the owners are
                  advancing the Donlin Gold project up the value chain and are
                  working toward a feasibility study decision, subject to Donlin
                  Gold LLC Board approval.
[[Image Removed]] A workshop with Barrick and NOVAGOLD will take place in
                  September at the Donlin Gold project in Alaska to review the
                  work completed to date and lay the path forward.

Statements by the Owners

Barrick President and Chief Executive Mark Bristow said, "as expected, the drill program for 2022 continues to enhance our understanding of the ore bodies that make up the Donlin project. Also encouraging is that this year's drilling campaign is ahead of schedule and results so far support the most recent modelling concepts as we focus on moving the project toward a feasibility study decision. I look forward to the Donlin Gold workshop in Alaska in September to advance these efforts."

Greg Lang, NOVAGOLD's President and CEO, said, "The 2022 drill program has been extremely exciting, not to mention rewarding. With the latest set of assays, we continue to enjoy some of the best gold intercepts in the mining industry. The outstanding results reported today, such as the high-grade at ACMA and the deep exploration work, further substantiate Donlin Gold's potential, and the recent modelling concepts, in support of the strategic mine planning work and the engineering studies. We have significantly de-risked Donlin Gold over many years, taking it up the value chain so as to Improve and enhance the value of the project for all our stakeholders. This progress is demonstrated through our commitment and dedication to building trust and transparency with our Alaska Native Corporation partners, Calista Corporation and The Kuskokwim Corporation, with whom we have created a model for responsible mining development."

Dan Graham, General Manager of Donlin Gold added, "Donlin Gold's top priorities continue to be the health and safety of our people following the best practices in environmental stewardship for the benefit of the people of Alaska. We could not be more pleased with the work of our 2022 Donlin Gold site crew. While exceeding productivity rates and running ahead of schedule, the overall morale of employees has been high and our safety record has remained strong. Moreover, we are most gratified to report that, during the program, the majority of our 150 employees and contractors were local hires from 24 Y-K communities in Alaska."

                                                                        Page | 1

Delivering Results

The prime focus of our activities this year is to undertake a 34,000-meter drill program with tight-spaced grid drilling as well as in-pit and ex-pit exploration; and to input the results from this drilling into the geologic modelling and interpretation work that is being used for updated resource models. In June, the Donlin Gold LLC Board approved an additional 43 drill holes and 8,380 meters to infill one of the 20-meter grids to 10-meter spacing. In addition to the engineering studies underway to support the mining schedules and life of mine business plans, this program will enable us to proceed with the preparation of an updated feasibility study, subject to a formal decision by the Donlin Gold LLC Board.

Following the excellent results of 2021, we are encouraged by the expanded drill program for 2022, with drilling also focused on upside prospects in the ACMA and Lewis pits where drilling so far has been limited. The new assays we received have thus far yielded some outstanding intercepts, with the five top intervals released today being:

   [[Image Removed]] DC22-2040 intersected 52.27 m grading 14.63 g/t gold starting
                     at 232.95 m drilled depth, including sub intervals of 13.94 m
                     grading 33.95 g/t gold starting at 232.95 m drilled depth and
                     16.45 m grading 13.50 g/t gold starting at 257.18 m drilled
                     depth;
   [[Image Removed]] DC22-2040 intersected 18.65 m grading 10.78 g/t gold starting
                     at 197.60 m drilled depth, including a sub interval of 7.68 m
                     grading 19.69 g/t gold starting at 199.35 m drilled depth;
   [[Image Removed]] DC22-2056 intersected 73.98 m grading 4.21 g/t gold starting
                     at 99.82 m drilled depth, including a sub interval of 6.16 m
                     grading 18.20 g/t gold starting at 109.12 m drilled depth;
   [[Image Removed]] DC22-2063 intersected 12.10 m grading 22.15 g/t gold starting
                     at 130.04 m drilled depth, including a sub interval of 5.43 m
                     grading 47.17 g/t starting 135.48 m drilled depth; and
   [[Image Removed]] DC22-2067 intersected 44.58 m grading 4.50 g/t gold starting
                     at 464.06 m drilled depth, including sub intervals of 3.11 m
                     grading 10.79 g/t gold starting at 464.06 m drilled depth and
                     6.35 m grading 10.26 g/t gold starting at 496.00 m drilled
                     depth.
[[Image Removed]] Drill-hole collar locations and five of the top intervals are
                  shown in Figure 1.
[[Image Removed]] Drill-hole orientations, depths and significant intervals are
                  shown in Tables 1 and 2, respectively, in the Appendix at the
                  end of this release.
[[Image Removed]] DC22-2063 interval is subparallel to a mineralized fault zone
                  and mineralized dyke.

[[Image Removed]] DC22-2067 interval is subparallel to a mineralized fault zone.

[[Image Removed]] The team of 150 people at Donlin Gold are advancing drilling
                  activities at a fine pace, with the drilling expected to
                  wrap-up in the fall. The health and safety of our workforce is
                  a priority. Donlin Gold has implemented strict safety
                  protocols, while COVID-19 mitigation measures remain in place
                  to ensure that the staff rotations in and out of the camp are
                  conducted in both an efficient and safe manner.

Donlin Gold 2022 Project Budget

The 2022 budget for Donlin Gold LLC (on a 100% basis) is set at $60 million, split equally between the two owners. The focus is to refresh geologic modelling and interpretation work for an updated resource model as well as engineering activities to inform an updated feasibility study decision. Approximately 34,000 meters of in-pit and below-pit drilling was planned under the original scope, in addition to fieldwork, for the Alaska Dam Safety Certifications, environmental studies, and external affairs efforts. An additional $4.8 million (100% basis) was approved by the Donlin Gold LLC Board for the additional 8,380 drill meter workplan.

                                                                        Page | 2

The owners will continue to advance the Donlin Gold project as they have done for many years in a financially disciplined manner with a clear focus on a strong safety culture, engineering excellence, environmental stewardship, and active community engagement.

About Donlin Gold

The Donlin Gold project is located in Alaska, the second largest gold-producing state in the United States. With approximately 39 million ounces of gold grading 2.24 grams per tonne in the measured and indicated mineral resource categories (100 percent basis)1, Donlin Gold hosts one of the largest and highest-grade undeveloped open-pit gold endowments in the world. The planned pits in which the existing resources are sited occupy only three kilometers of an eight-kilometer mineralized belt, which itself is located on less than 5% of Donlin Gold's land position. Current activities at Donlin Gold are focused on the drill program, optimization efforts, community outreach, and advancing the remaining State permitting actions.

Donlin Gold is a committed partner to the Alaska Native communities both surrounding the project and within the State as a whole. This commitment underpins our approach and is also reflected in the way in which the asset itself is structured. An important factor that distinguishes Donlin Gold from most other mining assets in Alaska is that the project is located on private land designated for mining activities under the 1971 Alaska Native Claims Settlement Act (ANCSA). Donlin Gold has entered into life-of-mine agreements with Calista, which owns the subsurface mineral rights and some surface land rights, and The Kuskokwim Corporation (TKC), a collection of 10 village corporations, which owns the majority of surface land rights. Donlin Gold is committed to providing employment opportunities, scholarships, and preferential contract considerations to Calista and TKC shareholders. The life-of-mine agreements include a revenue-sharing structure established in the context of the ANCSA, which resolved Alaska Native land claims and allotted some 44 million acres of land for use by Alaska Native Corporations. Additionally, our long-term commitment to economic development in the Y-K region is exemplified by Donlin Gold's support of TKC's initiative to launch energy and infrastructure projects in middle Kuskokwim villages. These partnerships, activities, and programs are illustrative of Donlin Gold's commitment to sustainable and responsible development of the project for the benefit of all stakeholders.

______________________________

1 Donlin Gold data as per the 2021 Technical Report and S-K 1300 Report (both as defined herein). Donlin Gold possesses Measured Resources of approximately 8 Mt grading 2.52 g/t and Indicated Resources of approximately 534 Mt grading 2.24 g/t, each on a 100% basis and inclusive of Mineral Reserves, of which approximately 4 Mt of Measured Resources and approximately 267 Mt of Indicated Resources inclusive of Reserves is attributable to NOVAGOLD through its 50% ownership interest in Donlin Gold LLC. Exclusive of Mineral Reserves, Donlin Gold possesses Measured Resources of approximately 1 Mt grading 2.23 g/t and Indicated Resources of approximately 69 Mt grading 2.44 g/t, of which approximately 0.5 Mt of Measured Resources and approximately 35 Mt of Indicated Resources exclusive of Mineral Reserves is attributable to NOVAGOLD. Donlin Gold possesses Proven Reserves of approximately 8 Mt grading 2.32 g/t and Probable Reserves of approximately 497 Mt grading 2.08 g/t, each on a 100% basis, of which approximately 4 Mt of Proven Reserves and approximately 249 Mt of Probable Reserves is attributable to NOVAGOLD. Mineral Reserves and Resources have been estimated in accordance with NI 43-101 and S-K 1300.

                                                                        Page | 3

FIGURE 1 Drill Hole Collar Locations

[[Image Removed]]

Depicted grid system is based on NAD83 UTM zone 4N coordinates. Longitudinal Section View orientation below taken at A - A' orientation depicted above.

                                                                        Page | 4

FIGURE 2 Longitudinal Section View of the ACMA and Lewis Deposits

[[Image Removed]]

QA/QC Procedures

The QA/QC procedures for the 2022 Donlin Gold project drill program and sampling protocol were developed and managed by Donlin Gold and overseen by Barrick and NOVAGOLD. The chain of custody from the drill site to the sample preparation facility was continuously monitored. All samples are HQ-diameter core. Approximately 94% core recovery has been achieved during the 2022 drill program. Core was logged, cut, and sampled at site by Donlin Gold employees. Samples were primarily collected on one- to two-meter lengths. Sampled half-core was crushed in Bureau Veritas' Juneau and Fairbanks, Alaska sample preparation facilities. Crushed samples were sent to Bureau Veritas' lab in Vancouver, British Columbia for pulverizing and gold assays and pulverized splits to an ALS Limited lab in Vancouver, British Columbia for multi-element analysis. Quality control samples were inserted (standards at 5% of primary samples, blanks at 5% of primary samples and duplicates at 2.5% of primary samples) into each batch of samples. The review of the quality control samples did not indicate any bias or error. Out of bounds quality control samples were handled with appropriate reruns and investigations. There are no known factors that would materially affect the accuracy or reliability of the drill program data referred to in this media release.

Downhole directional surveys were completed on all reported completed holes by Boart Longyear drill operators, and collar surveys were completed by Donlin Gold staff under the supervision of Professional Licensed Surveyors from Brice Engineering LLC.

Each of Bureau Veritas, ALS Limited, Boart Longyear, and Brice Engineering LLC are independent of Donlin Gold, Barrick, and NOVAGOLD.

Scientific and Technical Information

In mid-2021, NOVAGOLD engaged Wood Canada Limited ("Wood") to update the Second Updated Feasibility Study on Donlin Gold completed in 2011 (the "2011 Technical Report"). This update resulted in a report titled "NI 43-101 Technical Report on the Donlin Gold Project, Alaska, USA" with an effective date of June 1, 2021 (the "2021 Technical Report"). In 2021, NOVAGOLD also engaged Wood to prepare a Donlin Gold technical report summary in accordance with Subpart 229.1300 of Regulation S-K - Disclosure by Registrants Engaged in Mining Operations ("S-K 1300") as of November 30, 2021. The resulting report is titled "S-K 1300 Technical Report Summary on the Donlin Gold Project, Alaska, USA" ("S-K 1300 Report"), current as of November 30, 2021. Wood incorporated 2020 costs and new gold price guidance to meet the NOVAGOLD's reporting requirements. The resultant 2021 Technical Report and S-K 1300 Report showed no material change to the previously reported mineral resources or mineral reserves.

                                                                        Page | 5

NOVAGOLD is a registrant with the SEC and is reporting its Mineral Resources and Mineral Reserves in accordance with S-K 1300 as of November 30, 2021. While the S-K 1300 rules are similar to National Instrument 43-101 Standards of Disclosure for Mineral Projects ("NI 43-101") rules in Canada, they are not identical and therefore two reports have been produced for the Donlin Gold project.

Certain scientific and technical information contained herein with respect to the Donlin Gold project is derived from the 2021 Technical Report and the S-K 1300 Report. Henry Kim, P.Geo., Senior Resource Geologist, Wood Canada Limited; Mike Woloschuk, P.Eng., VP Global Business Development & Consulting, Wood Group USA, Inc.; and Kirk Hanson, MBA, P.E., Technical Director, Open Pit Mining, Wood Group USA, Inc. are the Qualified Persons responsible for the preparation of the 2021 Technical Report, and each is an independent Qualified Person as defined by National Instrument 43-101 ("NI 43-101"). Wood prepared the S-K 1300 Report.

Paul Chilson, P.E., who is the Manager of Mine Engineering for NOVAGOLD and a Qualified Person under NI 43-101, has approved and Checked the scientific and technical information related to the 2021 and 2022 Donlin Gold project drill programs, the 2021 Technical Report and the S-K 1300 Report contained in this media release. To verify the information related to the drilling programs, he has visited the property in the past year; discussed logging, sampling, and sample shipping processes with responsible site staff; discussed and reviewed assay and QA/QC results with responsible personnel; and reviewed supporting documentation, including drill hole location and orientation and significant assay interval calculations.

Octavia Bath, P.Geo., who is a Barrick Mineral Resource Manager and a Qualified Person under NI 43-101 has reviewed and approved the assay results for the Donlin Gold project contained in this media release.

Barrick Contacts:

Kathy du Plessis

Investor and Media Relations

+44 20 7557 7738

Email: barrick@dpapr.com

Kevin Annett

CFO, North America

Tel: +1 416-307-3660

www.barrick.com

NOVAGOLD Contacts:

Melanie Hennessey Vice President, Corporate Communications

Tel: +1 604-669-6227 or 1-866-669-6227

Email: info@novagold.com

www.novagold.com

                                                                        Page | 6

Cautionary Note Regarding Forward-Looking Statements

This media release includes certain "forward-looking information" and "forward-looking statements" (collectively "forward-looking statements") within the meaning of applicable securities legislation, including the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements are frequently, but not always, identified by words such as "expects", "anticipates", "believes", "intends", "estimates", "potential", "possible", and similar expressions, or statements that events, conditions, or results "will", "may", "could", "would" or "should" occur or be achieved. Forward-looking statements are necessarily based on several opinions, estimates and assumptions that management of Barrick and NOVAGOLD considered appropriate and reasonable as of the date such statements are made, are subject to known and unknown risks, uncertainties, assumptions, and other factors that may cause the actual results, activity, performance, or achievements to be materially different from those expressed or implied by such forward-looking statements. All statements, other than statements of historical fact, included herein are forward-looking statements. These forward-looking statements include statements regarding assay results; the anticipated timing of a decision by the Board of Donlin Gold LLC to prepare a feasibility study update; anticipated benefits from recent drill programs including an improved geological model for Donlin Gold; the work program for the 2022 field season; the continuing priorities of Donlin Gold, including the health and safety of our people; ongoing support provided to key stakeholders including Native Corporation partners; the potential impact of the coronavirus global pandemic (COVID-19) on the development of Donlin Gold; the potential development and construction of Donlin Gold; the sufficiency of funds to continue to advance development of Donlin Gold; perceived merit of properties; mineral reserve and resource estimates; Donlin Gold's ability to secure the permits needed to construct and operate the Donlin Gold project in a timely manner, if at all; and legal challenges to Donlin Gold's existing permits. In addition, any statements that refer to expectations, intentions, projections or other characterizations of future events or circumstances are forward-looking statements. Forward-looking statements are not historical facts but instead represent the management expectations of Donlin Gold's, Barrick's and NOVAGOLD's estimates and projections regarding future events or circumstances on the date the statements are made.

Important factors that could cause actual results to differ materially from expectations include the need to obtain additional permits and governmental approvals; the timing and likelihood of securing permits; the need for additional financing to explore and develop properties and availability of financing in the debt and capital markets; the spread and impact of COVID-19; uncertainties involved in the interpretation of drill results and geological tests and the estimation of reserves and resources; exploitation and exploration successes; changes in national and local government legislation, taxation, controls or regulations and/or changes in the administration of laws, policies and practices, expropriation or nationalization of property and political or economic developments in the United States or Canada; the need for continued cooperation between Barrick and NOVAGOLD for the continued exploration, development and eventual construction of the Donlin Gold project; the need for cooperation of government agencies and native groups in the development and operation of properties; risks of construction and mining projects such as accidents, equipment breakdowns, bad weather, disease pandemics, non-compliance with environmental and permit requirements, unanticipated variation in geological structures, ore grades or recovery rates; unexpected cost increases, which could include significant increases in estimated capital and operating costs; fluctuations in metal prices and currency exchange rates; whether a positive construction decision will be made regarding Donlin Gold; and other risks and uncertainties disclosed in Barrick's most recent Form 40-F/Annual Information Form on file with the United States Securities and Exchange Commission (SEC) and Canadian provincial securities authorities, and NOVAGOLD's most recent reports on Forms 10-K and 10-Q, particularly the "Risk Factors" sections of those reports and other documents filed by Barrick and NOVAGOLD with applicable securities regulatory authorities from time to time. Copies of these filings may be obtained by visiting NOVAGOLD's website at www.novagold.com, Barrick's website at www.barrick.com, or the SEC's website at www.sec.gov, or at www.sedar.com. The forward-looking statements contained herein reflect the beliefs, opinions, and projections of Donlin Gold, NOVAGOLD, and Barrick on the date the statements are made. Donlin Gold, NOVAGOLD and Barrick assume no obligation to update the forward-looking statements of beliefs, opinions, projections, or other factors, should they change, except as required by law.

                                                                        Page | 7
                                    APPENDIX

TABLE 1

Drill Hole Orientations* and Depths

HOLE Azimuth () Inclination () Depth (m) DC22-2033 331 61 254.51 DC22-2034 331 62 287.43 DC22-2035 238 45 877.52 DC22-2036 328 59 245.06 DC22-2037 335 59 289.86 DC22-2038 331 61 248.72 DC22-2039 331 56 289.26 DC22-2040 333 60 309.37 DC22-2041 331 61 261.82 DC22-2042 336 58 264.57 DC22-2043 329 60 230.12 DC22-2044 331 59 288.34 DC22-2045 331 60 224.94 DC22-2046 333 60 239.57 DC22-2047 331 59 230.12 DC22-2048 331 61 166.73 DC22-2049 331 61 145.24 DC22-2050 333 59 219.46 DC22-2051 242 52 851.61 DC22-2052 335 61 139.90 DC22-2053 334 59 292.91 DC22-2054 334 60 188.37 DC22-2055 335 62 215.19 DC22-2056 334 60 184.40 DC22-2057 335 59 244.45 DC22-2058 332 61 196.90 DC22-2059 339 60 234.85 DC22-2060 330 59 157.28 DC22-2061 331 59 247.80 DC22-2062 332 60 239.88 DC22-2063 334 58 300.38 DC22-2064 334 58 230.12 DC22-2065 332 59 225.55 DC22-2066 334 59 225.55 DC22-2067 246 52 777.54 DC22-2068 333 62 240.18 DC22-2069 333 61 260.60 DC22-2070 332 60 240.79 DC22-2071 330 61 225.55 DC22-2072 333 59 223.88

                                                                        Page | 8

DC22-2073 330 61 233.17 DC22-2074 332 61 240.03 DC22-2075 330 59 233.78 DC22-2076 333 60 227.99 DC22-2077 330 61 211.68 DC22-2078 333 59 230.12 DC22-2079 334 61 235.00 DC22-2080 332 58 256.34 DC22-2081 332 59 239.88 DC22-2082 245 54 789.43 DC22-2083 328 64 220.07 DC22-2084 335 62 209.09 DC22-2085 334 57 249.94 DC22-2086 334 58 210.31 DC22-2087 332 56 220.37 DC22-2088 334 59 219.46 DC22-2089 332 59 243.84 DC22-2090 330 58 220.07 DC22-2091 334 60 260.30 DC22-2092 333 59 225.55 DC22-2093 334 59 235.00 DC22-2094 327 63 915.10 DC22-2095 335 58 199.95 DC22-2096 332 60 275.84 DC22-2097 256 70 483.11 DC22-2098 337 58 199.95 DC22-2099 333 58 227.38 DC22-2100 334 57 216.56 DC22-2101 311 64 522.43 DC22-2102 331 60 227.08 DC22-2103 330 61 291.08 DC22-2104 330 60 239.57 DC22-2105 336 59 275.84 DC22-2106 324 62 920.95 DC22-2107 334 60 265.18 DC22-2108 294 67 557.78 DC22-2109 334 62 303.28 DC22-2110 331 61 289.56 DC22-2111 332 61 245.36 DC22-2113 334 63 259.99 DC22-2114 334 61 256.95 DC22-2115 334 60 311.05

* Note that azimuth and inclination values vary as each hole progresses. The stated values are hole averages, rounded to the nearest degree.

                                                                        Page | 9

TABLE 2

2021 Donlin Gold Significant Assay Intervals

 Hole ID  Area   From      To     Length  Au Grade (g/t)
               (Meters) (Meters) (Meters)
DC22-2033 ACMA    33.04    36.50     3.46           1.24
DC22-2033         42.17    50.01     7.84           2.79
DC22-2033        105.65   126.32    20.67           2.76
DC22-2033        172.08   176.43     4.35           1.03
DC22-2033        185.79   189.64     3.85           1.87
DC22-2033         TOTAL             40.17           2.36
DC22-2034 ACMA    44.35    48.16     3.81           1.78
DC22-2034        116.29   129.32    13.03           6.40
including        121.31   127.97     6.66          10.51
DC22-2034        140.80   145.80     5.00          10.39
DC22-2034        208.38   220.88    12.50           2.18
DC22-2034         TOTAL             34.34           4.93
DC22-2035 ACMA   433.53   440.95     7.42           6.30
DC22-2035        651.24   682.65    31.41           3.81
DC22-2035        751.88   756.10     4.22           8.15
DC22-2035         TOTAL             43.05           4.67
DC22-2036 ACMA   137.33   144.48     7.15           3.39
DC22-2036        152.57   159.29     6.72           2.94
DC22-2036         TOTAL             13.87           3.17
DC22-2037 ACMA   109.24   119.58    10.34           3.07
DC22-2037         TOTAL             10.34           3.07
DC22-2038 ACMA   114.50   126.63    12.13           3.24
DC22-2038        185.16   190.15     4.99           4.90
DC22-2038         TOTAL             17.12           3.72
DC22-2039 ACMA   122.46   126.13     3.67           3.46
DC22-2039         TOTAL              3.67           3.46
DC22-2040 ACMA    97.26   105.21     7.95           2.77
DC22-2040        114.45   122.41     7.96           1.50
DC22-2040        139.25   154.84    15.59           3.64
DC22-2040        197.60   216.25    18.65          10.78
including        199.35   207.03     7.68          19.69
DC22-2040        232.95   285.22    52.27          14.63
including        232.95   246.89    13.94          33.95
including        257.18   273.63    16.45          13.50
DC22-2040         TOTAL            102.42          10.31
DC22-2041 ACMA    75.03    81.99     6.96           4.60
DC22-2041         86.43   101.36    14.93           1.82
DC22-2041        105.74   113.42     7.68           4.43
DC22-2041        174.29   187.45    13.16           7.47
DC22-2041         TOTAL             42.73           4.48
                                                                       Page | 10

DC22-2042 ACMA 19.80 34.44 14.64 3.09 DC22-2042 95.10 102.28 7.18 3.71 DC22-2042 152.80 162.62 9.82 2.93 DC22-2042 168.21 187.81 19.60 4.06 DC22-2042 196.04 205.46 9.42 5.22 DC22-2042 TOTAL 60.66 3.78 DC22-2043 ACMA 49.61 58.38 8.77 7.23 DC22-2043 144.97 168.48 23.51 6.20 DC22-2043 TOTAL 32.28 6.48 DC22-2044 ACMA 26.21 30.14 3.93 2.78 DC22-2044 157.31 166.42 9.11 3.62 DC22-2044 171.95 176.69 4.74 4.55 DC22-2044 TOTAL 17.78 3.69 DC22-2045 ACMA 12.53 18.23 5.70 3.95 DC22-2045 41.42 58.40 16.98 1.56 DC22-2045 63.84 73.05 9.21 2.40 DC22-2045 128.03 133.50 5.47 3.18 DC22-2045 138.75 146.20 7.45 1.74 DC22-2045 158.22 170.45 12.23 1.93 DC22-2045 205.38 213.77 8.39 1.92 DC22-2045 TOTAL 65.43 2.16 DC22-2046 ACMA 24.38 32.42 8.04 5.25 DC22-2046 109.52 135.25 25.73 5.22 DC22-2046 176.88 194.04 17.16 3.48 DC22-2046 207.43 212.14 4.71 1.32 DC22-2046 220.58 223.77 3.19 1.02 DC22-2046 TOTAL 58.83 4.18 DC22-2047 ACMA 37.19 47.66 10.47 2.37 DC22-2047 135.33 140.13 4.80 9.08 including 136.37 140.13 3.76 11.06 DC22-2047 151.83 176.24 24.41 3.76 DC22-2047 TOTAL 39.68 4.04 DC22-2048 ACMA 6.44 10.48 4.04 5.16 DC22-2048 23.77 30.48 6.71 7.43 DC22-2048 36.88 43.61 6.73 3.48 DC22-2048 94.64 106.83 12.19 3.11 DC22-2048 111.17 143.61 32.44 1.18 DC22-2048 TOTAL 62.11 2.74 DC22-2049 ACMA 10.97 16.20 5.23 6.51 DC22-2049 95.70 112.44 16.74 2.76 DC22-2049 TOTAL 21.97 3.65 DC22-2050 ACMA 38.40 42.93 4.53 1.22 DC22-2050 98.40 123.70 25.30 2.82 DC22-2050 137.98 162.88 24.90 2.74 DC22-2050 TOTAL 54.73 2.65

                                                                       Page | 11

DC22-2051 ACMA 69.70 80.01 10.31 1.27 DC22-2051 119.52 126.19 6.67 1.72 DC22-2051 343.75 356.05 12.30 3.24 DC22-2051 437.45 474.88 37.43 2.35 DC22-2051 533.86 565.30 31.44 4.63 including 545.90 550.40 4.50 11.45 DC22-2051 693.27 708.65 15.38 6.81 including 698.89 703.53 4.64 16.59 DC22-2051 746.67 767.93 21.26 3.74 DC22-2051 TOTAL 134.79 3.58 DC22-2052 ACMA 6.36 17.07 10.71 2.43 DC22-2052 100.72 104.92 4.20 1.93 DC22-2052 TOTAL 14.91 2.29 DC22-2053 ACMA 39.82 43.55 3.73 2.24 DC22-2053 50.55 59.82 9.27 2.09 DC22-2053 169.41 172.63 3.22 3.72 DC22-2053 286.82 290.15 3.33 2.57 DC22-2053 TOTAL 19.55 2.47 DC22-2054 ACMA 10.05 13.42 3.37 3.44 DC22-2054 108.52 148.31 39.79 3.37 DC22-2054 152.89 179.89 27.00 2.70 DC22-2054 TOTAL 70.16 3.11 DC22-2055 ACMA 12.19 35.77 23.58 2.36 DC22-2055 115.85 124.30 8.45 5.11 DC22-2055 131.99 152.88 20.89 4.12 DC22-2055 181.66 187.45 5.79 2.03 DC22-2055 TOTAL 58.71 3.35 DC22-2056 ACMA 2.44 13.33 10.89 17.55 including 7.01 11.13 4.12 44.11 DC22-2056 83.31 86.37 3.06 8.51 DC22-2056 99.82 173.80 73.98 4.21 including 109.12 115.28 6.16 18.20 DC22-2056 TOTAL 87.93 6.02 DC22-2057 ACMA 10.97 21.25 10.28 2.59 DC22-2057 40.56 48.17 7.61 1.97 DC22-2057 52.57 60.64 8.07 1.05 DC22-2057 118.89 123.88 4.99 2.23 DC22-2057 135.23 142.04 6.81 6.04 DC22-2057 147.74 160.25 12.51 3.91 DC22-2057 166.47 173.36 6.89 2.48 DC22-2057 186.43 194.98 8.55 4.04 DC22-2057 TOTAL 65.71 3.09 DC22-2058 ACMA 5.18 14.02 8.84 2.81 DC22-2058 21.46 33.01 11.55 3.50 DC22-2058 112.19 118.57 6.38 3.84 DC22-2058 124.23 138.62 14.39 8.18 including 130.24 136.99 6.75 15.15 DC22-2058 151.79 172.17 20.38 2.83 DC22-2058 TOTAL 61.54 4.31

                                                                       Page | 12

DC22-2059 Divide 57.65 76.04 18.39 3.64 DC22-2059 81.48 86.56 5.08 1.01 DC22-2059 95.38 109.70 14.32 2.75 DC22-2059 118.26 122.22 3.96 2.94 DC22-2059 TOTAL 41.75 2.95 DC22-2060 ACMA 10.02 16.48 6.46 7.99 DC22-2060 116.69 121.75 5.06 2.26 DC22-2060 TOTAL 11.52 5.47 DC22-2061 Divide 22.80 25.91 3.11 2.36 DC22-2061 32.72 41.90 9.18 2.10 DC22-2061 55.87 66.97 11.10 2.59 DC22-2061 73.76 81.30 7.54 1.80 DC22-2061 91.09 129.15 38.06 3.08 DC22-2061 172.94 176.31 3.37 2.49 DC22-2061 186.10 196.08 9.98 2.51 DC22-2061 TOTAL 82.34 2.67 DC22-2062 Divide 54.25 87.49 33.24 1.02 DC22-2062 110.99 115.21 4.22 4.76 DC22-2062 126.31 132.65 6.34 9.68 DC22-2062 147.06 197.82 50.76 3.28 DC22-2062 TOTAL 94.56 2.98 DC22-2063 Divide 9.14 15.75 6.61 1.32 DC22-2063 61.13 75.81 14.68 3.12 DC22-2063 130.04 142.14 12.10 22.15 including 135.48 140.91 5.43 47.17 DC22-2063 TOTAL 33.39 9.66 DC22-2067 ACMA 83.17 92.99 9.82 1.43 DC22-2067 123.01 130.91 7.90 2.41 DC22-2067 145.78 160.87 15.09 5.49 DC22-2067 251.68 260.64 8.96 1.05 DC22-2067 273.14 288.11 14.97 1.94 DC22-2067 416.80 434.50 17.70 4.26 DC22-2067 464.06 508.64 44.58 4.50 including 464.06 467.17 3.11 10.79 including 496.00 502.35 6.35 10.26 DC22-2067 582.22 592.53 10.31 2.82 DC22-2067 614.40 626.58 12.18 1.16 DC22-2067 644.08 652.25 8.17 1.79 DC22-2067 724.00 730.65 6.65 1.05 DC22-2067 TOTAL 156.33 3.17

                                                                       Page | 13

DC22-2082 ACMA 20.56 47.61 27.05 2.53 DC22-2082 60.07 68.99 8.92 2.26 DC22-2082 88.83 94.25 5.42 2.23 DC22-2082 130.34 136.86 6.52 3.71 DC22-2082 400.20 407.52 7.32 2.67 DC22-2082 423.91 427.27 3.36 7.32 DC22-2082 555.07 564.83 9.76 7.75 DC22-2082 568.85 583.94 15.09 3.35 DC22-2082 632.16 641.42 9.26 2.85 DC22-2082 660.08 668.73 8.65 2.19 DC22-2082 684.64 701.30 16.66 4.29 DC22-2082 718.02 724.88 6.86 5.77 DC22-2082 TOTAL 124.87 3.62

Significant intervals represent drilled intervals and not necessarily true thickness of mineralization. Mineralized intervals meet or exceed 3 meters in length above 1 g/t. A maximum of 4 meters of continuous dilution (< 1 g/t) is permitted. Assays from DC22-2033, DC-22-2034, DC22-2036 through DC22-2050, DC22-2052 through DC22-2058, and DC22-2060 represent holes from the 20-meter spaced West ACMA grid drilling and DC22-2059, DC22-2061 through DC22-2066, DC22-2068 through DC22-2081, DC22-2083 through DC22-2088, DC22-2090, DC22-2092, and DC22-2093 represent holes from the Divide 20-meter spaced grid drilling. DC22-2063 interval is subparallel to the mineralized fault zone and mineralized dyke. DC22-2067 interval is subparallel to a mineralized fault zone. Any drill intervals not depicted in this table did not meet the significant interval criteria. Assay data are not yet available from 122.79 m to 234.85 m in DC22-2059, 150.82 m to 300.38 m in DC22-2063, and all of holes DC22-2064 through DC22-2066, DC22-2068 through DC22-2081, and DC22-2083 through DC22-2115.

                                                                       Page | 14

Jul 28, 2022

COMTEX_411192567/2254/2022-07-28T18:40:19

Is there a problem with this press release? Contact the source provider Comtex at editorial@comtex.com. You can also contact MarketWatch Customer Service via our Customer Center.

(c) 1995-2022 Cybernet Data Systems, Inc. All Rights Reserved

The MarketWatch News Department was not involved in the creation of this content.

Thu, 28 Jul 2022 06:39:00 -0500 en-US text/html https://www.marketwatch.com/press-release/8-k-novagold-resources-inc-2022-07-28
Killexams : Druva Once Again Named a Visionary by Gartner, Recognized for Ability to Execute and Completeness of Vision

Company Positioned as a Visionary for the Second Consecutive Year in the 2022 Gartner® Magic Quadrant™ for Enterprise Backup and Recovery Software Solutions

SANTA CLARA, Calif.–(BUSINESS WIRE)–Druva Inc. today announced it has been positioned by Gartner as a Visionary in the 2022 Gartner Magic Quadrant for Enterprise Backup and Recovery Software Solutions for the second consecutive year.¹ Druva was recognized for its Ability to Execute and Completeness of Vision and believes this year’s inclusion further validates the company’s innovative, SaaS-based approach to data protection that frees customers from hardware, software, and management.

Global organizations today are facing unprecedented challenges. While economic uncertainties and supply chain disruptions continue to exacerbate hardware availability, millions of IT positions remain unfilled due to a lack of skilled talent, leaving IT organizations with limited resources. Combined with advancing cyber threats, businesses need a more efficient, cost-effective approach to protect their critical data.

Delivering a mature, at-scale SaaS solution, the Druva Data Resiliency Cloud helps organizations minimize these challenges and gain greater control over their data through a secure, simplified approach. Additionally, Druva’s data management capabilities Improve visibility and maximize storage efficiencies, while its consumption-based licensing enables organizations to reduce costs and scale needs on demand. When combined with its industry-leading approach to security, Druva helps thousands of leading organizations advance their data, cyber and operational resilience.

“Almost a decade ago, Druva recognized the potential of disrupting a hardware-based business model with a radically simple SaaS platform built completely in the cloud,” said Jaspreet Singh, founder and CEO, Druva. “Since then, we have continued to introduce industry-first innovations that enhance business agility with zero complexity or infrastructure cost. We feel this recognition is a testament to all the hard work our team has accomplished, and is further validation of the shifting landscape before us. Simplicity, visibility, time to value and cost savings are key to the future of data protection, and we are ready to meet these needs through the Data Resiliency Cloud.”

Customers Reduce TCO by 50% and Achieve Faster Time to Value with the Druva Data Resiliency Cloud:

  • Best IT Decision I Have Ever Made – “Deploying Druva backup solution was the easiest backup deployment I have ever done. The administration and setup was easy and the interface relatively intuitive. I have performed several restores with no issues. Expansion of backup sets is very easy as well. Choosing Druva was one of the best IT decisions I have ever made.”
  • Fast, Efficient, Affordable Backup Solution – “Druva was so easy and fast to implement. Restores have been very easy to trigger when necessary. Product is constantly being updated. Really happy with our decision to go with Druva.”
  • Data Protection Without Additional Hardware Dependence – “Druva enables us to properly backup our on premise VMware environment without the need to grow our on premise footprint to support backups. When we acquire a new company, we can get their systems protected with Druva in a day.”

View a complimentary copy of the Magic Quadrant report to learn more about Druva Data Resiliency Cloud’s strengths and cautions, among other provider offerings, here.

Additional Information

  • Free Trial: Register for a 30-day free trial of the Druva Data Resiliency Cloud
  • Customer Reviews: See what customers are saying about Druva on Gartner Peer Insights

¹Gartner, “Magic Quadrant for Enterprise Backup and Recovery Software Solutions,” Nik Simpson, Michael Hoeck, Jerry Rozeman, Jason Donham, 29 July 2022.

Gartner Disclaimer:

GARTNER and Magic Quadrant are registered trademarks and service marks of Gartner, Inc. and/or its affiliates in the U.S. and internationally and are used herein with permission. All rights reserved.

Gartner Peer Insights content consists of the opinions of individual end users based on their own experiences, and should not be construed as statements of fact, nor do they represent the views of Gartner or its affiliates. Gartner does not endorse any vendor, product or service depicted in this content nor makes any warranties, expressed or implied, with respect to this content, about its accuracy or completeness, including any warranties of merchantability or fitness for a particular purpose.

Gartner does not endorse any vendor, product or service depicted in our research publications, and does not advise technology users to select only those vendors with the highest ratings or other designation. Gartner research publications consist of the opinions of Gartner’s research organization and should not be construed as statements of fact. Gartner disclaims all warranties, expressed or implied, with respect to this research, including any warranties of merchantability or fitness for a particular purpose.

About Druva

Druva enables cyber, data and operational resilience for every organization with the Data Resiliency Cloud, the industry’s first and only at-scale SaaS solution. Customers can radically simplify data protection, streamline data governance, and gain data visibility and insights as they accelerate cloud adoption. Druva pioneered a SaaS-based approach to eliminate complex infrastructure and related management costs, and deliver data resilience via a single platform spanning multiple geographies and clouds. Druva is trusted by thousands of enterprises, including 60 of the Fortune 500 to make data more resilient and accelerate their journey to cloud. Visit druva.com and follow us on LinkedIn, Twitter and Facebook.

Contacts

Media Contact:
Jesse Caputo

Director of Corporate Communications

Druva Inc.

+1.516.815.2836

jesse.caputo@druva.com

Wed, 03 Aug 2022 06:02:00 -0500 it-IT text/html https://www.01net.it/druva-once-again-named-a-visionary-by-gartner-recognized-for-ability-to-execute-and-completeness-of-vision/
Killexams : A conversation with the Maritime and Port Authority of Singapore (MPA)

For the transport sector to reach net zero, the global shipping industry must keep pace

Founded in 1996, the mission of the Maritime and Port Authority of Singapore (MPA) is to develop Singapore as a premier global port hub and a leading international maritime centre, and to advance and safeguard Singapore’s strategic maritime interests.

Global shipping now contributes to around 2.89% of global emissions, according to the International Maritime Organization’s (IMO) Fourth Greenhouse Gas Study1. These emissions add to the greenhouse effect and many countries in the Asia-Pacific region are already starting to experience the adverse effects of climate change. In 2001, major flooding was caused along the south eastern Malaysia Peninsular when Typhoon Vamei, the first recorded cyclone in the region, hit near the equator. As global warming continues, rising sea levels are threatening vital infrastructure and communities – including Singapore. To offset the worst potential effects of climate catastrophe, the IMO has set a clear target of reducing the shipping industry’s GHG emissions by at least 50% by 2050.

As the world’s largest bunkering port and a major transhipment hub, Singapore has an important role to play in the decarbonisation of the shipping sector. MPA will continue to support this agenda by enabling a multi-fuel transition and believes that the key to accelerating the development of low-carbon fuels is through collaboration between stakeholders.

Pioneering the next fleet of sustainable ports and vessels

A decade ago, MPA became the world’s first maritime administration to launch a comprehensive pro-environment initiative. The Maritime Singapore Green Initiative (MSGI) aimed to promote clean and green shipping in Singapore, and since its inception, the programme has been reviewed and enhanced twice to ensure it is up to date with the latest in climate technology and risk.

Singapore is located at the cross-roads of the East-West trade and sits within the seven-hour flight radius to many emerging Asian markets. MPA capitalises on this strategic location by encouraging green development through five key programmes, which has achieved considerable results to date:

1.  The Green Port Programme (GPP) encourages ships to use cleaner fuels in Singapore through a reduction in port dues. As at 2019, the GPP has also achieved considerable success, with more than 4,700 vessel calls having switched to marine fuel with sulphur content not exceeding 1%. Between January 2020 to December 2021, over 700 vessel calls have benefited from the enhanced MSGI programme.

2. The Green Ship Programme (GSP) incentivises green ship design beyond IMO’s requirements through tax rebates. As at 2020, more than 600 Singapore-flagged ships have qualified for GSP.

3. MPA launched Maritime Greenfuture Fund (GFF) in 2020. The S$40 million fund seeks to accelerate efforts in the development and commercialisation of technologies supporting maritime decarbonisation. A total co-funding of some S$9 million was set aside under the GFF to support up to 3 harbour craft electrification projects. In 2021, MPA and SMI jointly awarded funding from the GFF to three consortiums led by Keppel FELS Limited, SeaTech Solutions and Sembcorp Marine, (comprising a total of 30 enterprises and research institutions) to research, design, build and operate a fully electric harbour craft over the next five years.

4. The Green Energy and Technology Programme (GETP) promotes pilot trials and technology development for maritime emissions reduction. Currently, the annual CO2 emission from the improved ships has been reduced by more than 177,000 tonnes.

5. The Green Awareness Programme (GAP) promotes awareness of sustainability reporting among maritime companies.

MPA understands that the journey to a more sustainable future will not be achieved in silos and is actively partnering with key stakeholders across the shipping industry to Improve the pace of change.

Recently, MPA’s MINT fund supported local SME, Billion Miles, and their test bedding partners to develop a novel bio-fuel methanol direct injection system. This class-approved novel design allows for a single injection for both fuel types, hence reducing the complexities of engine design and subsequent expected maintenance costs. 


Greener leadership

As a sector in which industry captains have strong leadership roles in charting the industry path, MPA, together with the Singapore Maritime Foundation set up an International Advisory Panel on Maritime Decarbonisation. The panel provided industry perspectives and recommendations to allow Singapore to support global maritime decarbonisation objectives and to create new opportunities for the industry. A mix of local and international C-suite leaders represent a cross-section of the maritime industry and academia provide their expert guidance and recommendations on how to decarbonise Maritime Singapore. Following the panel’s recommendation in April 2021, MPA announced the formation of the Global Centre for Maritime Decarbonisation (GCMD) in Singapore and its leadership team with effect from 1 August 2021.

The centre was set to spearhead the maritime industry’s energy transition journey with a S$120 million fund from MPA and six founding partners namely BHP, BW Group, Eastern Pacific Shipping, Foundation Det Norske Veritas, Ocean Network Express and Sembcorp Marine. GCMD aims to collaborate with the industry to help the maritime sector reduce GHG emissions, implement identified decarbonisation pathways and create new business opportunities.

Singapore will continue to grow as a sustainable global hub port and support the decarbonisation of international shipping. A multi-fuel transition will be achieved by providing regulatory sandboxes to support trials of alternate fuels, and in line with the whole-of-government approach on decarbonisation, scale up bunkering infrastructure to offer multiple zero/low-carbon fuel solutions.

The backbone of global trade

Marine insurance is a key enabler of global trade and provides the shipping sector with the assurance that it needs to allow commerce to function. The availability of new insurance products can influence decision making by injecting greater confidence among investors to pursue new areas of developments, such as electric vessels.

Lloyd’s has been underwriting marine insurance business for over 330 years and remains a leading market for this class globally.  In 1999, Lloyd’s Asia was established in Singapore and has grown to become Lloyd’s largest underwriting platform, playing an important role in promoting Singapore’s development as a hub for maritime services and insurance. In addition to its substantial business presence, Lloyd’s Asia also collaborates with marine and shipping associations and government agencies in Singapore to enhance the understanding of risk management and marine insurance, including with the MPA which has played an important role in enabling the establishment and growth of Lloyd’s Asia’s marine underwriting capabilities.

MPA is actively bringing organisations together in joint projects to catalyse and co-create maritime decarbonisation solutions across the value chain. They also welcome increased engagement from marine insurers to work with Singapore’s shipping industry. Lloyd’s, MPA and Lloyd’s Singapore underwriters plan to collaborate on marine decarbonisation research to further support the sector. By working together, MPA believes that we can increase momentum in green shipping, achieving a united approach towards decarbonisation.

Marine innovation can help the sector with its transition to a greener future

Maritime decarbonisation is a global challenge requiring a concerted effort from all stakeholders across the value chain, and MPA believes the industry will need to explore multiple decarbonisation pathways to achieve this. To outline Singapore’s long-term strategies for a sustainable maritime industry, MPA has developed the Maritime Singapore Decarbonisation Blueprint 2050 in partnership with industry stakeholders to chart out decarbonisation strategies.

Internationally, Singapore will advance strong and credible climate action, by facilitating partnerships to develop pragmatic solutions. Today, Liquefied Natural Gas (LNG) as a marine fuel remains a key and immediate mean for the maritime industry to reduce its carbon emissions during this low-carbon transition.

As the world’s premier maritime hub, Singapore will continue its role as a global leader in the maritime decarbonisation space, paving the way for the broader industry. As Singapore continues its transition towards a low-carbon future, building on its experience with establishing LNG bunkering, MPA will play a pivotal role in setting up further trials and pilots, with the aim of developing other commercially viable and even greener fuel solutions.

Using the experiences gained through its varied initiatives, Singapore will also support global collaboration in wider critical areas such as regulation, international networks, and the scaling-up of supply chains, to support the industry’s transition into a low-carbon future. The Lloyd’s market will continue to support Singapore, MPA and the Asia-Pacific region with the insurance products needed to support the transition.

1 International Maritime Organization’s (IMO) Fourth Greenhouse Gas Study - Fourth Greenhouse Gas Study

Sun, 03 Apr 2022 05:30:00 -0500 en text/html https://www.lloyds.com/news-and-insights/futureset/join-the-reset/greener-transport/mpa-case-study/
Killexams : Gander Gold Identifies Potential Major New Gold Trend East of Keats and Appleton Zones

VANCOUVER, BC / ACCESSWIRE / August 5, 2022 / As the 2022 exploration program continues at its 485 sq. km Gander North Project in Newfoundland, Gander Gold Corp. ("Gander Gold" or the "Company") (CSE:GAND)(OTCQB:GANDF) has identified a potential major new gold trend within the Gander Gold Belt starting approximately 12 km east of the GRUB Line and 25 km east of the Appleton trend that hosts the New Found Gold and Labrador Gold high-grade discoveries.

Highlights:

  • A main northeast-trending strike-slip shear zone extends more than 25 km across Gander North and remains open to the northeast;

  • Numerous north-northeast trending dilational zones also cut across Gander North and could add significant economic potential to the property;

  • In total, these zones already provide greater than 100 linear kilometers of structure which is highly prospective for gold;

  • Abundant geochemical anomalies generated from 8,273 soil and till samples (2021) coincide with results from a recently completed airborne Mag/VLF geophysical survey and a LiDAR survey;

  • 192 soil samples ranged in grade between 25.1 ppb Au and 1,432 ppb Au, considered high for Newfoundland;

  • The best outcropping quartz veins, identified initially with high resolution satellite and aerial photos, occur within the dilational zones and represent immediate targets for ground follow-up.

Gander Gold, which launched on the CSE in March of this year, has a combined ownership of 63% between Sassy Gold (35.3 million shares, 48.3%) and Eric Sprott (10.6 million shares, 14.6%).

Shawn Ryan, Gander Gold Technical Adviser, commented: "Broad areas of Gander North are lighting up from our Phase 1 Soil Sampling Program. Results from our 2021 Airborne Mag/VLF and LiDAR surveys are in and have been very helpful in adding the next layer of detail interpretation needed to advance the Phase 2 soil work."

Mr. Ryan continued, "It is remarkable how this previously unexplored area has suddenly become a ‘hot spot' for potential new gold discoveries in Newfoundland along what clearly appears to be an entirely new gold trend east of the GRUB Line. We eagerly anticipate results from this summer's work as we progress toward RAB drilling to prioritize the most prospective diamond drilling targets."

Mr. Ian Fraser, Gander Gold VP-Exploration, added: "Our Phase 2 soil geochemistry program will consist of additional soil sampling to extend the known anomalies along strike, and to sample in greater detail in and around some of the most elevated gold-in-soil anomalies. Furthermore, there are numerous other interpreted structures we will test with soil geochemistry. From top to bottom, Gander North is revealing itself as an important area for potential new high-grade gold discoveries on the island."

Gander North Soils/Structures

Gander Gold Corporation, Friday, August 5, 2022, Press release picture

To view a short video clip from Shawn Ryan on developments at Gander North, please visit GanderGold.com or use this direct link:

https://www.youtube.com/watch?v=cccdDoOxYPc

Soil Program Results & Interpretation

Soil geochemistry sampling performed perpendicular to numerous lineaments at Gander North has revealed multiple gold-in-soil anomalies directly over and within these lineaments. Gander Gold is very encouraged that initial detailed sampling along these lineaments has highlighted areas within a single lineament where continuous gold-in-soil anomalies occur over a significant distance. These first-pass gold-in-soil anomalies occur at areas interpreted to be of greater structural complexity and are thus viewed to be more favourable to host potential gold deposits.

The Viking target (refer to December 8, 2021, Sassy Resources news release) has been extended to the southeast with additional sampling. Results up to 370 ppb Au-in-soil indicate a fertile environment for mineralization continuing to the southeast of the original Viking discovery.

The additional soil geochemistry sampling in the Viking target area was designed to cover the known historic Jonathan's Third Pond Copper Occurrence. Prospecting within the Jonathan's Third Pond Copper Occurrence identified a wide zone of silicification 600 m x 500 m containing quartz veining, sericite alteration and up to 5% pyrite and 0.5% chalcopyrite and trace galena. Assay results returned values up to 0.50 g/t Au, 4,670 ppm Pb, and 1,785 ppm Cu, suggesting this area is prospective for base metals in additional to gold. The Jonathan's Third Pond Copper Occurrence trend aligns with a northeast-trending lineament extending more than 20 km in potential strike across the Gander North Project.

Quality Assurance / Quality Control

Gander Gold Corporation has contracted the services of GroundTruth Exploration to conduct its soil geochemistry programs in Newfoundland. Soil samples are collected at pre-determined sites, placed in soil sample bags and all metadata associated with a sample is recorded. Once sorted and logged, samples are shipped to Eastern Analytical in Springdale Newfoundland for sample preparation. At Eastern Analytical individual samples are dried and sieved and 50g splits are prepared and then shipped by courier to Bureau Veritas Commodities Canada Ltd. (Bureau Veritas) in Vancouver British Columbia for analyses. Eastern Analytical and Bureau Veritas are ISO / IEC 17025 certified laboratories and independent of Gander Gold Corporation. At Bureau Veritas the 15g splits are partially digested by aqua regia digestion and analysed for gold plus 36 additional elements by ICP-ES/MS (method AQ201). GroundTruth Exploration crews took a field duplicate every 25th sample and these field duplicates were inserted into the sample stream to monitor the quality of analyses for the soil sampling program. In addition, the lab was requested to do Repeat analyses at multiple intervals within the sampling stream.

Qualified Person

The technical information in this news release has been reviewed and approved by Mr. Ian Fraser, P.Geo., Vice President of Exploration for Gander Gold. Mr. Fraser is the Qualified Person responsible for the scientific and technical information contained herein under National Instrument 43-101 standards.

Corporate Video

To view the Gander Gold corporate video, visit GanderGold.com or use this direct link:

https://youtu.be/DLeHGZSkjWQ

About Gander Gold Corporation

Gander Gold is an exploration stage resource company currently engaged in the identification, acquisition and exploration of high-grade precious metal and base metal projects in the Central Newfoundland Gold Belt. Its focus is on its eight projects in the Canadian province of Newfoundland & Labrador, namely the Gander North, Mt. Peyton, Cape Ray II, BLT, Carmanville, Gander South, Little River and Hermitage projects, which comprise 9,032 claims or approximately 2,257 km², making Gander Gold Corporation one of the largest claimholders in Newfoundland.

Caution Regarding Forward Looking Statements

Investors are cautioned that, except for statements of historical fact, certain information contained in this document includes "forward looking information", with respect to a performance expectation for Sassy Resources Corporation. Such forward looking statements are based on current expectations, estimates and projections formulated using assumptions believed to be reasonable and involving a number of risks and uncertainties which could cause actual results to differ materially from those anticipated. Such factors include, without limitation, fluctuations in foreign exchange markets, the price of commodities in both the cash market and futures market, changes in legislation, taxation, controls and regulation of national and local governments and political and economic developments in Canada and other countries where Sassy carries out or may carry out business in the future, the availability of future business opportunities and the ability to successfully integrate acquisitions or operational difficulties related to technical activities of mining and reclamation, the speculative nature of exploration and development of mineral deposits, including risks obtaining necessary licenses and permits, reducing the quantity or grade of reserves, adverse changes in credit ratings, and the challenge of title. The Company does not undertake an obligation to update publicly or revise forward looking statements or information, whether as a result of new information, future events or otherwise, unless so required by applicable securities laws. Some of the results reported are historical and may not have been Checked by the Company.

Contact Info:

Mark Scott
Chief Executive Officer & Director
info@gandergold.com

Terry Bramhall
Gander Gold - Corporate Communications
1.604.833.6999 (mobile)
1.604.675.9985 (office)
terry.bramhall@gandergold.com

The CSE has neither approved nor disapproved the contents of this news release. Neither the CSE nor its Regulation Services Provider (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this news release.

SOURCE: Gander Gold Corporation

View source version on accesswire.com:
https://www.accesswire.com/710943/Gander-Gold-Identifies-Potential-Major-New-Gold-Trend-East-of-Keats-and-Appleton-Zones

Sat, 06 Aug 2022 10:08:00 -0500 en-CA text/html https://ca.news.yahoo.com/gander-gold-identifies-potential-major-115500446.html
Killexams : Oracle and Microsoft Announce Availability of Oracle Database Service for Microsoft Azure

Oracle partners with Microsoft to supply Azure customers direct, streamlined access to Oracle databases on Oracle Cloud Infrastructure

AUSTIN, Texas and REDMOND, Wash., July 20, 2022 /PRNewswire/ -- Oracle Corp and Microsoft Corp today announced the general availability of Oracle Database Service for Microsoft Azure. With this new offering, Microsoft Azure customers can easily provision, access, and monitor enterprise-grade Oracle Database services in Oracle Cloud Infrastructure (OCI) with a familiar experience. Users can migrate or build new applications on Azure and then connect to high-performance and high-availability managed Oracle Database services such as Autonomous Database running on OCI.

Oracle Database Service for Microsoft Azure

Offering Customers Choice with Azure and OCI Multicloud Capabilities

Over the last two decades, thousands of customers have relied on Microsoft and Oracle software working well together to run their business-critical applications. As customers migrate applications and data to the cloud, they continue to look for joint solutions from their trusted software partners. Since 2019, when Oracle and Microsoft partnered to deliver the Oracle Interconnect for Microsoft Azure, hundreds of organizations have used the secure and private interconnections in 11 global regions.

Microsoft and Oracle are extending this collaboration to further simplify the multicloud experience with Oracle Database Service for Microsoft Azure. Many joint customers, including some of the world's largest corporations such as AT&T, Marriott International, Veritas and SGS, want to choose the best services across cloud providers to optimize performance, scalability, and the ability to accelerate their business modernization efforts. The Oracle Database Service for Microsoft Azure builds upon the core capabilities of the Oracle Interconnect for Azure and enables customers to more easily integrate workloads on Microsoft Azure with Oracle Database services on OCI. There are no charges for using the Oracle Database Service for Microsoft Azure, the Oracle Interconnect for Microsoft Azure or data egress or ingress when moving data between OCI and Azure. Customers will pay only for the other Azure or Oracle services they consume, such as Azure Synapse or Oracle Autonomous Database.

"Microsoft and Oracle have a long history of working together to support the needs of our joint customers, and this partnership is an example of how we offer customer choice and flexibility as they digitally transform with cloud technology. Oracle's decision to select Microsoft as its preferred partner deepens the relationship between our two companies and provides customers with the assurance of working with two industry leaders," said Corey Sanders, corporate vice president, Microsoft Cloud for Industry and Global Expansion.

"There's a well-known myth that you can't run real applications across two clouds. We can now dispel that myth as we supply Oracle and Microsoft customers the ability to easily test and demonstrate the value of combining Oracle databases with Azure applications. There is no need for deep skills on either of our platforms or complex configurations—anyone can use the Azure Portal to harness the power of our two clouds together," said Clay Magouyrk, executive vice president, Oracle Cloud Infrastructure.

"Multicloud takes on a whole new meaning with the launch of the Oracle Database Service for Microsoft Azure. This service, designed to provide intuitive, simple access to the Exadata Database Service and Autonomous Database to Azure users in a transparent manner, responds to the critical need of Azure and Oracle customers to apply the benefits of the latest in Oracle Database technology to their Azure workloads. This combined and interactive connection of services across public clouds sets the stage for what a multicloud experience should be, and is a bold statement about where the future of cloud is heading. It should deliver huge benefits for customers, developers, and the cloud services landscape overall," said Carl Olofson, research vice president, Data Management Software, IDC.

Familiar Experience for Azure Users Combined with an Oracle Managed Service

With the new Oracle Database Service for Microsoft Azure, in just a few clicks users can connect their Azure subscriptions to their OCI tenancy. The service automatically configures everything required to link the two cloud environments and federates Azure Active Directory identities, making it easy for Azure customers to use the service. It also provides a familiar dashboard for Oracle Database Services on OCI using Azure terminology and monitoring with Azure Application Insights.

"Many of our mission-critical workloads are running Oracle databases on-premises at massive scale. As we move these workloads to the cloud, Oracle Database Service for Azure enables us to modernize these Oracle databases to services such as Autonomous Database in OCI while leveraging Microsoft Azure for the application tier," said Jeremy Legg, chief technology officer, AT&T. Watch the video.

"Multicloud architectures enable us to choose the best cloud provider for each workload based on capabilities, performance, and price. The OCI and Azure partnership integrates the capabilities of two major cloud providers, including the Oracle Database services in OCI and Azure's application development capabilities," said Naveen Manga, chief technology officer, Marriott International. Watch the video.

"Oracle Database Service for Microsoft Azure has simplified the use of a multicloud environment for data analytics. We were able to easily ingest large volumes of data hosted by Oracle Exadata Database Service on OCI to Azure Data Factory where we are using Azure Synapse for analysis," said Jane Zhu, senior vice president and chief information officer, Corporate Operations, Veritas.

"Oracle Database Service for Microsoft Azure simplifies our multicloud approach. We're going to be able to leverage the best of Oracle databases in Azure, and we are going to be able to keep our infrastructure in Azure. This is a great opportunity to have the best of the two worlds that eases our migration to the cloud and improves the skills of our people in IT," said David Plaza, chief information officer, SGS. Watch the video.

Additional Resources

About Oracle

Oracle offers integrated suites of applications plus secure, autonomous infrastructure in the Oracle Cloud. For more information about Oracle (NYSE: ORCL), please visit us at oracle.com.

About Microsoft

Microsoft (Nasdaq "MSFT" @microsoft) enables digital transformation for the era of an intelligent cloud and an intelligent edge. Its mission is to empower every person and every organization on the planet to achieve more.

Trademarks

Oracle, Java, and MySQL are registered trademarks of Oracle Corporation.

Contact Info

Carolin Bachmann
Oracle PR
+1.415.622.8466
carolin.bachmann@oracle.com

Microsoft Media Relations
WE Communications for Microsoft
+1 425 638 7777
rapidresponse@we-worldwide.com

Cision

View original content to download multimedia:https://www.prnewswire.com/news-releases/oracle-and-microsoft-announce-availability-of-oracle-database-service-for-microsoft-azure-301589773.html

SOURCE Oracle

Wed, 20 Jul 2022 00:18:00 -0500 en-CA text/html https://ca.finance.yahoo.com/news/oracle-microsoft-announce-availability-oracle-121500988.html
VCS-413 exam dump and training guide direct download
Training Exams List